# Synthesis of pyrido[2,3-b]indoles and pyrimidoindoles via

# Pd-catalyzed amidation and cyclization

Arepalli Sateesh Kumar, P.V. Amulya Rao and Rajagopal Nagarajan\*

School of Chemistry, University of Hyderabad

Hyderabad-500046, India

E-mail: rnsc@uohyd.ernet.in

## **SUPPORTING INFORMATION**

Table of Contents	<u>Page</u>
General Information	S2
General Procedures	S2-S7
Materials	<b>S7</b>
Tables S1A, S1B, S2A, S2B, S3A, Computational studies, FIGURES	
S2, S3, S4, & S5 (IR & GC-MS spectra)	S8-S18
References	S19
Analytical data	S20-S47
Spectra	S48-S238
Computational Outputs	S239-S243

#### **General Information:**

The procedure does not require inert atmosphere. All the amide products obtained were purified by column chromatography using silica gel (100-200 mesh). Hexane was used as a co-eluent. <sup>1</sup>H and <sup>13</sup>C NMR were recorded in 400 and 100 MHz spectrometer respectively. The chemical shifts are reported in ppm downfield to TMS ( $\delta = 0$ ) for <sup>1</sup>H NMR and relative to the central CDCl<sub>3</sub> resonance ( $\delta = 77.0$ ) for <sup>13</sup>C NMR. IR spectra were recorded on FT/IR. Elemental analyses were recorded on Flash EA 1112 analyzer in School of Chemistry, University of Hyderabad. Mass spectra were recorded on either VG7070H mass spectrometer using EI technique or LCMS-2010 mass spectrometer. Melting points were measured in open capillary tubes and are uncorrected.

# General procedure for the coupling of 1-benzyl-3-chloro-1*H*-indole-2carbaldehyde and thiophene-2-carboxamide:

An oven dried Ace Pressure tube with Teflon stir bar was charged with  $Pd_2(dba)_3$  (5.7 mg, 1.85  $\mu$ mol, 2.0 mol % Pd), BINAP (5.0 mg, 0.92  $\mu$ mol, 0.5 mol %), thiophene-2-carboxamide (28 mg, 0.07 mmol) and base [Cs<sub>2</sub>CO<sub>3</sub> (195 mg) or K<sub>3</sub>PO<sub>4</sub> (127 mg) or K<sub>2</sub>CO<sub>3</sub> (83 mg) or *t*-BuOK (58 mg), 1-benzyl-3-chloro-1H-indole-2-carbaldehyde (0.05g ,0.185 mmol) and *t*-BuOH (2.0 mL) and then capped with a Teflon screw cap and the mixture was heated to 110 °C with stirring for 8 h. At this point, the reaction mixture was allowed to cool to room temperature, diluted with ethyl acetate, and the resulting solution was filtered through celite, and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (eluting with hexanes/ethyl acetate) to give the corresponding coupled product (**1e**).

# General procedure for the coupling of 3-bromo-1-ethyl-1*H*-indole-2carbaldehyde and benzamide:

An oven dried Ace Pressure tube with Teflon stir bar was charged with  $Pd_2(dba)_3$  (1.3 mg, 1.4 µmol, 1.0 mol % Pd), BINAP (0.60 mg, 0.9 µmol, 0.25 mol %), benzamide (28 mg, 0.239 mmol) and base [Cs<sub>2</sub>CO<sub>3</sub> (195 mg) or K<sub>3</sub>PO<sub>4</sub> (127 mg) or K<sub>2</sub>CO<sub>3</sub> (83 mg) or *t*-BuOK (58 mg), 3-bromo-1-ethyl-1H-indole-2-carbaldehyde (0.05g ,0.199 mmol) and toluene (2.0 mL) and then capped with a Teflon screw cap and the mixture was heated to 110 °C with stirring for 8 h. At this point, the reaction mixture was allowed to cool to room temperature, diluted with ethyl acetate, and the resulting solution was filtered through celite, and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (eluting with hexanes/ethyl acetate) to give the corresponding coupled product (**1a**).

# General procedure for the coupling of 2-bromo-1-ethyl-1*H*-indole-3carbaldehyde and thiophene-2-carboxamide:

An oven dried Ace Pressure tube with Teflon stir bar was charged with  $Pd_2(dba)_3$  (0.9 mg, 0.99 µmol, 1.0 mol % Pd), BINAP (0.31 mg, 0.49 µmol, 0.25 mol %), thiophene-2-carboxamide (30 mg, 0.239 mmol) and base [Cs<sub>2</sub>CO<sub>3</sub> (195 mg) or K<sub>3</sub>PO<sub>4</sub> (127 mg) or K<sub>2</sub>CO<sub>3</sub> (83 mg) or *t*-BuOK (58 mg), 2-bromo-1-ethyl-1H-indole-3-carbaldehyde (0.2g ,5.9 µmol) and *t*-BuOH (2.0 mL) and then capped with a Teflon screw cap and the mixture was heated to 110 °C with stirring for 8 h. At this point, the reaction mixture was allowed to cool to room temperature, diluted with ethyl acetate, and the resulting solution was filtered through celite, and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (eluting with hexanes/ethyl acetate) to give the corresponding coupled product (**1f**).

# General procedure for the coupling of 3-halo-indole-2-carbaldehyde and amide:

An oven dried Ace Pressure tube with Teflon stir bar was charged with  $Pd_2(dba)_3$  (if X = Cl, 1.0 mol %, 2.0 mol % Pd, if X = Br, 0.75 mol %, 1.5 mol % Pd), BINAP (0.50 mol %), amide (1.2 equiv) and  $Cs_2CO_3$  (3.0 equiv), 3-halo-indole-2-carbaldehyde (1.0 equiv) and if X = Br, toluene (1.0 mL); X = Cl, *t*-BuOH (2.0 mL) and then capped with a Teflon screw cap and the mixture was heated to 110 °C with stirring according to mentioned time in Table 1. At this point, the reaction mixture was allowed to cool to room temperature, diluted with ethyl acetate, and the resulting solution was filtered through celite, and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (eluting with hexanes/ethyl acetate) to give the corresponding coupled product.

#### General procedure for the coupling of 2-halo-3-carbonylindoles and amide:

An oven dried Ace Pressure tube with Teflon stir bar was charged with  $Pd_2(dba)_3$  (0.50 mol %, 1.0 mol % Pd), BINAP (0.25 mol %), amide (1.2 equiv) and  $Cs_2CO_3$  (3.0 equiv), 2-halo-3-carbonylindoles (1.0 equiv) and if X = Br, toluene (2.0 mL); X = Cl, *t*-BuOH (2.0 mL) and then capped with a Teflon screw cap and the mixture was heated to 110 °C with stirring according to mentioned time in Table 1. At this point, the reaction mixture was allowed to cool to room temperature, diluted with ethyl acetate, and the resulting solution was filtered through celite, and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (eluting with hexanes/ethyl acetate) to give the corresponding coupled product.

# General procedure for base-promoted cyclization to 2-substitued-4-hydroxy- $\alpha$ -carbolines:

An oven dried Ace Pressure tube with Teflon stir bar was charged with *N*-(3-acetyl-1-(substituted)-1*H*-indol-2-yl)amides (1.0 equiv) and *t*-BuOK (5.0 equiv) in THF (6 mL). The pressure tube was then sealed with a Teflon screw-cap and the reaction was placed in a preheated oil bath at 110 °C. The reaction mixture was stirred for according to mentioned time in Table 2 and then removed from the oil bath and allowed to cool to room temperature. The reaction mixture was then diluted with ethyl acetate. The resultant reaction mixture was extracted with EtOAc (20 mL), washed with water (100 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed *in vacuo* to obtain the pure product (2**a-2j**). Hexane was added and removed twice more before the product was dried *in vacuo*.

# General procedure for the one-pot synthesis of pyrimido[4,5-*b*] & [5,4*b*]indoles (Method A):

An oven dried Ace Pressure tube with Teflon stir bar was charged with  $Pd_2(dba)_3$  (1.3 mg, 1.4 µmol, 1.0 mol % Pd), BINAP (0.18 mg, 2.9 µmol, 1.5 mol %), amide (86 mg, 0.07 mmol) and base [Cs<sub>2</sub>CO<sub>3</sub> (195 mg) or K<sub>3</sub>PO<sub>4</sub> (127 mg) or K<sub>2</sub>CO<sub>3</sub> (83 mg) or *t*-BuOK (58 mg), 3-halo-2-formylindoles or 2-halo-3-carbonylindoles (0.2g ,5.9 µmol) and *t*-BuOH (2.0 mL) and then capped with a Teflon screw cap and the mixture was heated to 110 °C with stirring and the reaction was monitored by TLC. When the starting material was completely consumed, the reaction mixture was cooled to <80 °C and HCOONH<sub>4</sub> (6.0 equiv) in *t*-BuOH (2 mL) was added in one portion. The resulting mixture was heated back to 110 °C and the reaction mixture was stirred for according time mentioned in Table 3. When the reaction was complete, reaction

mixture was allowed to cool to room temperature, diluted with ethyl acetate, and the resulting solution was filtered through celite, and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (eluting with hexanes/ethyl acetate) to give the corresponding pyrimido[4,5-*b*] & [5,4-*b*]indole product.

# General procedure for the one-pot synthesis of pyrimido[4,5-b] & [5,4b]indoles (Method B):

An oven dried Ace Pressure tube with Teflon stir bar was charged with *N*-(3-carbonyl-1-(substituted)-1*H*-indol-2-yl)amides or *N*-(1-(substituted)-2-formyl-1*H*-indol-3-yl)amides (1.0 equiv) and HCOONH<sub>4</sub> (6.0 equiv) in *t*-BuOH (6 mL). The pressure tube was then sealed with a Teflon screw-cap and the reaction was placed in a preheated oil bath at 110 °C. The reaction mixture was stirred for according to mentioned time in Table 4 and then removed from the oil bath and allowed to cool to room temperature. The reaction mixture was then diluted with ethyl acetate. The resultant reaction mixture was extracted with EtOAc (20 mL), washed with water (100 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed *in vacuo* to obtain the pure product (**3a-3t**). Hexane was added and removed twice more before the product was dried *in vacuo*.

### General procedure for the synthesis of dihydropyrido[4,5-*b*]indoles:

A R.B. flask with Teflon stir bar charged with N-(3-formyl-1-(substituted)-1H-indol-2yl)amides (1.0 mmol), nitro styrene (1.0 mmol) and DABCO (0.5 mmol) were mixed under stirring and heated at 70 °C for 3h. After the reaction was over, the residue was diluted with dichloromethane, adsorbed on silicagel and subjected to column chromatography to obtain the **4a-b** in good yields.

#### Materials:

The starting materials 3-carbonyl-2-haloindole<sup>1</sup> and 2-formyl-3-haloindole<sup>2</sup> were prepared based on the literature procedures.

**Table S1A** Optimization of the Pd-catalyzed cross-coupling of 1-benzyl-3-chloro-1*H*-indole-2-carbaldehyde and thiophene-2-carboxamide <sup>a</sup>



Entry	Pd source-Ligand	Solvent	Base	Time (h)	Yield $(\%)^a$
1	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	t-BuOH	Cs <sub>2</sub> CO <sub>3</sub>	12	62 <sup>b</sup>
2	$Pd_2(dba)_3 - BINAP$	DMF	Cs <sub>2</sub> CO <sub>3</sub>	24	-
3	$Pd_2(dba)_3 - BINAP$	DMSO	$Cs_2CO_3$	24	-
4	$Pd_2(dba)_3 - BINAP$	toluene	$Cs_2CO_3$	24	40 <sup>b</sup>
5	$Pd_2(dba)_3 - BINAP$	toluene	$K_2CO_3$	24	32 <sup>b</sup>
6	$Pd_2(dba)_3 - PPh_3$	t-BuOH	$Cs_2CO_3$	24	-
7	$Pd_2(dba)_3$ - $Pcy_3$	t-BuOH	Cs <sub>2</sub> CO <sub>3</sub>	24	10
8	Pd(OAc) <sub>2</sub> - BINAP	toluene	$Cs_2CO_3$	24	14
9	$Pd(OAc)_2 - Pcy_3$	toluene	Cs <sub>2</sub> CO <sub>3</sub>	24	trace
10	$PdCl_2 - Pcy_3$	toluene	Cs <sub>2</sub> CO <sub>3</sub>	24	-
11	$PdCl_2(PPh_3)_2$	toluene	$Cs_2CO_3$	24	-
12	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	toluene	Cs <sub>2</sub> CO <sub>3</sub>	20	46 <sup>c</sup>
13	$Pd_2(dba)_3 - BINAP$	toluene	$K_2CO_3$	24	42
14	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	t-BuOH	$K_2CO_3$	10	85°
15	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	t-BuOH	Cs <sub>2</sub> CO <sub>3</sub>	8	<b>92</b> <sup>c</sup>
16	$Pd_2(dba)_3 - BINAP$	toluene	Cs <sub>2</sub> CO <sub>3</sub>	15	60 <sup>°</sup>
17	$Pd_2(dba)_3 - BINAP$	t-BuOH	$K_3PO_4$	12	83°

Conditions: 1-benzyl-3-chloro-1*H*-indole-2-carbaldehyde (1.0 mmol), thiophene-2-carboxamide (1.2 mmol), Pd (2.0 mol %), ligand (1.0 mol %), base (3.0 mmol), solvent (2.0 mL/mmol), 110 °C, 8-24 h. [a] isolated yields. [b]  $Pd_2(dba)_3$  (0.50 mol %), BINAP (0.25 mol %), [c]  $Pd_2(dba)_3$  (1.0 mol %), BINAP (0.50 mol %)

**Table S1B** Optimization of the Pd-catalyzed cross-coupling of 3-bromo-1-ethyl-1*H*-indole-2-carbaldehyde and benzamide, 2-bromo-1-ethyl-1*H*-indole-3-carbaldehyde and thiophene-2-carboxamide



Entry	Pd source-Ligand	Solvent	Base	Time (h)	Yield (%) <sup>a</sup>
1	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	t-BuOH	$Cs_2CO_3$	24	1a (49); 1f (62)
2	$Pd_2(dba)_3 - BINAP$	THF	Cs <sub>2</sub> CO <sub>3</sub>	24	1a (18); 1f (27)
3	$Pd_2(dba)_3 - BINAP$	dioxane	Cs <sub>2</sub> CO <sub>3</sub>	24	1a (15); 1f (21)
4	$Pd_2(dba)_3 - BINAP$	DMF	Cs <sub>2</sub> CO <sub>3</sub>	24	1a (-); 1f (-)
5	$Pd_2(dba)_3 - BINAP$	DMSO	Cs <sub>2</sub> CO <sub>3</sub>	24	1a (-); 1f (-)
6	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	dioxane	$Cs_2CO_3$	24	1a (12); 1f (20)
7	$Pd_2(dba)_3 - PPh_3$	t-BuOH	$Cs_2CO_3$	26	1a (57); 1f (62)
8	$Pd_2(dba)_3 - Pcy_3$	t-BuOH	Cs <sub>2</sub> CO3	20	1a (57); 1f (62)
9	$Pd_2(dba)_3 - Pcy_3$	toluene	Cs <sub>2</sub> CO <sub>3</sub>	18	1a (78); 1f (83)
10	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	toluene	Cs <sub>2</sub> CO <sub>3</sub>	10	1a (81) <sup>b</sup> ;1f(94) <sup>b</sup>
11	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	toluene	$Cs_2CO_3$	6	1a (90) <sup>c</sup> ;1f (94) <sup>b</sup>
12	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	toluene	$K_3PO_4$	15	1a (51); 1f (64)
13	Pd <sub>2</sub> (dba) <sub>3</sub> - BINAP	toluene	$K_2CO_3$	24	1a (56); 1f (65)
14	Pd(OAc) <sub>2</sub> - BINAP	toluene	Cs <sub>2</sub> CO <sub>3</sub>	24	1a (55); 1f (70)
15	$Pd(OAc)_2 - PPh_3$	toluene	$K_2CO_3$	24	1a (42); 1f (48)
16	$Pd(OAc)_2 - Pcy_3$	toluene	$K_2CO_3$	24	1a (45); 1f (53)
17	$PdCl_2 - Pcy_3$	toluene	$K_2CO_3$	24	1a (11); 1f (26)
18	$PdCl_2(PPh_3)_2$	toluene	$Cs_2CO_3$	24	1a (-); 1f (-)

Conditions: 3-bromo-1-ethyl-1*H*-indole-2-carbaldehyde (1.0 mmol), benzamide (1.2 mmol), Pd (1.5 mol %), ligand (0.75 mol %), 2-bromo-1-ethyl-1*H*-indole-3-carbaldehyde (1.0 mmol), thiophene-2-carboxamide (1.2 mmol), Pd (1 mol %), ligand (0.25 mol %), base (3.0 mmol), solvent (2.0 mL/mmol), 110 °C, 6-24 h. [a] isolated yields. [b]  $Pd_2(dba)_3$  (0.50 mol %), BINAP (0.25 mol %), [c]  $Pd_2(dba)_3$  (0.75 mol %), BINAP (0.50 mol %)

Table S2A Optimization for the synthesis of 9-ethyl-2-methyl-9H-pyrido[2,3-b]indol-4-ol <sup>a</sup>



Entry	Base	Solvent	Temp (°C)	Time (h)	Yield $(\%)^{b}$
1	Cs <sub>2</sub> CO <sub>3</sub>	t-BuOH	110	24	25
2	NaOH	THF	70	24	12
3	NaOH	t-BuOH	110	24	16
4	NaOH	DMF	110	24	-
5	NaOH	dioxane	110	24	12
6	NaOEt	toluene	110	24	-
7	$Cs_2CO_3$	THF	70	24	40
8	NaOMe	dioxane	110	24	-
9	NaOAc	t-BuOH	110	24	20
10	t-BuOK	MeOH	70	24	47
11	t-BuOK	THF	70	6	88
12	t-BuOK	dioxane	110	24	42
13	t-BuOK	toluene	110	24	13
14	t-BuOK	DMF	110	24	20

<sup>a</sup>Conditions: *N*-(3-acetyl-1-ethyl-1*H*-indol-2-yl)acetamide (1.0 mmol) and base (5.0 mmol), solvent (2.0 mL/mmol), 70-110 °C, 6-24 h. [b] Isolated yields.

#### **Computational Analysis:**

Generally, aliphatic carbonyl compounds which have alpha hydrogens undergo *keto-enol* tautomerism; among them the *keto* form is favored over the *enol* form due to the stabilization of the C=O bond. Though, this common fashion is not obeyed by the cyclic conjugated ketone systems. In this tautomerism, the *enol* form is predominant over *keto* form albeit literature <sup>3</sup>also supports the existence of the *enol* form almost exclusively. This conclusion was achieved by performing electronic structure calculations on the isomers of these molecules.



Density functional theory (DFT) hybrid method with the Becke's 3 parameter exchange functional of Lee, Yang and Parr (B3LYP) and 6-31+G(D) (valence double zeta plus polarization functions of d type) basis set is used to optimize the geometries of the two tautomers of the 9ethyl-2-methyl-1H-pyrido[2,3-b]indol-4(9H)-one. The effect of solvation also studied here. Three types (gas phase, using methanol and tetra hydro furan as solvents with polarizable continuum model (PCM) solvent model) of calculations are done on the two tautomers. All the calculations were done using Gaussian 09 package. It is well recognized that this method and basis set are reliable for organic molecules. The two structures converged to a minimum and both minima were verified by establishing that the matrix of energy second derivatives (Hessian) has only positive Eigen values (all vibrational frequencies real). The optimized keto and enol forms are depicted by **Fig S2a & S2b**. The transition state is verified by the presence of only one large negative vibrational frequency (-1671cm<sup>-1</sup>). The obtained transition state is depicted in **Fig S2c**. The electronic and activation energies of the two tautomers and transition states in the three models of theory are tabulated in Table S2B.



Fig S2. B3LYP and 6-31+G(D) Optimized (a) keto form (b) enol form (c) transition state

Table S2B. The total energy of the Keto, Enol and Transition states at B3LYP/6-

31+G(D) level of theory in gas phase and solvent

Method	Keto form	Enol form	Transition	Activation Energy
	(Hartree)	(Hartree)	State (Hartree)	(K.cal/mol)
Gas Phase	-726.6992284	-726.7088136	-726.3832852ª	198.255
Methanol	-726.7225416	-726.7177769	-726.6256917	60.774
THF	-726.8643483	-726.8604681	-726.7665929	61.342

<sup>a</sup> The transition state was optimized with B3LYP method and 6-31g basis set but reactant and product were optimized with B3LYP method and 6-31+G(D) basis. Because the transition state search with 6-31+G(D) is unsuccessful.

From the Table S2B, it can be seen that the relative energy difference between the enol forms to keto form is very small. While the enol form is stable in gas phase than keto form by 6.011 Kcal/mol, the keto form is stable than the enol form by ~3 Kcal/mol in the solvent model. This stabilization can be attributed to the hydrogen bonding by the keto group with methanol. The relative energies are very small enough to be in equilibrium with the other counterpart even at room temperature. But in our synthesis only enol form is predominant than the keto form. So, we optimized the transition state for the conversion, the energies are tabulated in Table S2B. The activation energy for keto-enol tautomerism is 198.255, 60.774, 61.342 Kcal/mol in the gas

phase and solvent models respectively. These energy barriers cannot be attained with room temperature energy. So, only one form is predominant. The variable temperature (VT-PXRD) spectroscopic studies also support this statement.



# Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is The Royal Society of Chemistry 2012



**Figure S3** (a) <sup>13</sup>C NMR of 2f in liquid state (DMSO), (b) Solid State <sup>13</sup>C NMR, (c) NOESY of 2f (d) VT-PXRD patterns of 2f on -30  $^{\circ}$ C to 110  $^{\circ}$ C.

The IR spectrum of the molecule shows a broad peak at  $\Delta v_{max} 3410 \text{ cm}^{-1}$ . This peak was assigned as an O-H vibration. The peak cannot be assigned for the N-H bond vibrational frequency (~3300 cm<sup>-1</sup>)

# Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is The Royal Society of Chemistry 2012



Figure S4. IR Spectrum of 2f

Although tautomerism is a difficult subject to study in the gas phase, we recorded the GCMS of **2f** which shows a fragment by elimination of OH (M-17). This indicates the presence of a OH group in **2f**.



Figure S5. GC-MS of 2f

Table S3A Optimization for the synthesis of 9-butyl-2,4-dimethyl-9*H*-pyrimido[4,5-*b*]indole <sup>a</sup>



Entry	Ammonia Source	Solvent	Temp (°C)	Time (h)	Yield (%) <sup>b</sup>
1	NH <sub>4</sub> OH	t-BuOH	110	24	45
2	$\rm NH_4OH$	THF	110	24	-
3	$\rm NH_4OH$	MeOH	110	24	10
4	NH <sub>4</sub> Cl	t-BuOH	110	24	12
5	NH <sub>4</sub> OAc	t-BuOH	110	24	40
6	NH <sub>4</sub> OAc	MeOH	80	24	17
7	NH <sub>4</sub> OAc	DMF	110	24	-
8	HCOONH <sub>4</sub>	t-BuOH	110	5	91
9	HCOONH <sub>4</sub>	MeOH	80	24	43
10	HCOONH <sub>4</sub>	MeCN	110	24	-
11	HCOONH <sub>4</sub>	DMF	110	24	-
12	HCOONH <sub>4</sub>	DMSO	110	24	-

<sup>a</sup>Conditions: *N*-(3-acetyl-1-ethyl-1*H*-indol-2-yl)acetamide (1.0 mmol) and NH<sub>3</sub> source (6.0 mmol), solvent (2.0 mL/mmol), 80-110 °C, 5-24 h. <sup>b</sup>Isolated yields.

#### **Quantum Yield Calculations:**

Quantum yield calculations have been done following the equation

$$\frac{\Phi_{sample}}{\Phi_{std.}} = \frac{A_{sample}}{A_{std.}} \times \frac{OD_{std.}}{OD_{sample}} \times \frac{\eta^{2 sample}}{\eta^{2 std.}}$$

where std. abbreviates for the standard (here quinine sulfate), A is the integrated emission intensity, O.D. stands for the optical density at the excited wavelength and  $\eta$  is the refractive index (for dichloromethane  $\eta = 1.424$  and for water solutions  $\eta = 1.333$ ). The excitations have been performed at iso-O.D. where the absorption curve of the sample intersects the same of quinine sulfate.

#### **References:**

- (1) (a) Lu, S. C.; Duan, X. Y.; Shi, Z. J.; Li, B.; Ren Y. W.; Zhang, W. Org. Lett. 2009, 11, 3902-3905. (b) Ketcha, D. M.; Lieurance, B.A.; Homan, D. F. J. J. Org. Chem. 1996, 61, 6523-6525.
- (2) Majo, V. J.; Perumal, P. T. J. Org. Chem. 1996, 61, 6523-6525.
- (3) A. S. Kumar, R. Nagarajan, Org. Lett. 2011, 6, 1398.

έt

### Analytical data for all new compounds

## *N*-(1-Ethyl-2-formyl-1*H*-indol-3-yl)benzamide (1a):

Pale brown solid

mp. 113-115 °C

IR (KBr): 3352, 3217, 2920, 1789, 1653, 1519, 1454, 1390, 1222, 1210, 1109, 918, 727 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.87 (s, 1H), 9.62 (s, 1H), 7.94 (d, 2H, *J* = 8.0 Hz), 7.74 (d, 1H, *J* = 8.0 Hz), 7.62 (d, 1H, *J* = 8.0 Hz), 7.47-7.43 (m, 1H), 7.29-7.20 (m, 4H), 3.92 (q, 2H, *J* = 8.0 Hz), 1.22 (t, 3H, *J* = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 189.2, 167.8, 136.2, 136.0, 134.8, 132.5, 132.4, 128.6, 127.8, 124.5, 123.0, 121.7, 121.6, 120.6, 110.4, 106.5, 38.2, 14.5.

LC-MS: m/z = 293 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>; C, 73.95; H, 5.52; N, 9.58 %; found: C, 73.85; H, 5.51; N, 9.45 %.

## *N*-(1-Butyl-2-formyl-1*H*-indol-3-yl)nicotinamide (1b):



<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 10.79 (s, 1H), 10.02 (s, 1H), 9.30 (s, 1H), 8.76 (s, 1H), 8.35 (d, 1H, J = 8.0 Hz), 7.99-7.97 (m, 1H), 7.39-7.28 (m, 4H), 4.11 (t, 2H, J = 8.0 Hz), 1.81-1.74 (m, 2H), 1.30-1.22 (m, 2H), 0.86 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 184.8, 165.0, 153.0, 149.0, 135.9, 134.5, 132.3, 128.7, 126.9, 125.0, 123.8, 123.4, 123.1, 119.1, 110.8, 44.9, 30.9, 20.1, 13.6.

LC-MS: m/z = 322 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{19}H_{19}N_3O_2$ ;

C, 71.01; H, 5.96; N, 13.08 %; found: C, 71.22; H, 5.89; N, 13.15 %.

#### *N*-(1-Butyl-2-formyl-1*H*-indol-3-yl)acetamide (1c):

H<sub>3</sub> Orange solid

mp. 131-133 °C

N CHO IR (KBr): 3317, 3222, 2950, 1795, 1655, 1562, 1498, 1329, 1225, 1209, *n*-Bu 1127, 919, 725 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.99 (s, 1H), 9.61 (s, 1H), 8.02 (d, 1H, J = 8.0 Hz), 7.33-7.24 (m, 3H), 4.09 (t, 2H, J = 8.0 Hz), 2.28 (s, 3H), 1.79-1.71 (m, 2H), 1.33-1.25 (m, 2H), 0.91 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 184.6, 170.5, 141.6, 134.3, 124.8, 123.8, 123.4, 123.0, 119.3, 110.7, 107.2, 44.4, 30.9, 20.1, 13.6.

LC-MS: m/z = 259 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{15}H_{18}N_2O_2$ ; C, 69.74; H, 7.02; N, 10.84 %; found: C, 69.81; H, 7.12; N, 10.76 %.

#### *N*-(1-Butyl-2-formyl-1*H*-indol-3-yl)thiophene-2-carboxamide (1d):



<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 10.66 (s, 1H), 10.12 (s, 1H), 7.93-7.91 (m, 2H), 7.65-7.38 (m, 2H), 7.32-7.29 (m, 2H), 7.19-7.17 (m, 1H), 4.33 (t, 2H, *J* = 8.0 Hz), 1.85-1.78 (m, 2H), 1.28-1.26 (m, 2H), 0.90 (t, 3H, *J* = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 184.3, 160.6, 142.2, 137.5, 134.5, 132.7, 132.5, 130.8, 129.2, 128.3, 125.4, 123.0, 117.7, 111.0, 45.7, 30.8, 20.1, 13.6.

LC-MS: m/z = 327 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S; C, 66.23; H, 5.56; N, 8.58 %; found: C, 66.38; H, 5.51; N, 8.49 %.

#### *N*-(1-Benzyl-2-formyl-1*H*-indol-3-yl)thiophene-2-carboxamide (1e):

Pale yellow solid

mp. 217-219 °C

сно

IR (KBr): 3259, 3120, 2845, 1763, 1669, 1632, 1529, 1427, 1372, 1209, 1109, 1012, 915, 739 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 10.62 (s, 1H), 10.22 (s, 1H), 7.95 (d, 1H, *J* = 8.0 Hz), 7.83-7.82 (m, 1H), 7.64-7.63 (m, 1H), 7.33-7.31 (m, 1H), 7.30-7.24 (m, 5H), 7.18-7.15 (m, 1H), 7.09-7.07 (m, 2H), 5.62 (s, 2H).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 185.6, 160.7, 142.3, 137.7, 136.0, 134.9, 134.4, 133.7,
133.1, 132.1, 130.8, 128.9, 128.3, 127.7, 126.8, 125.5, 123.2, 117.8, 111.6, 105.2, 49.4.

LC-MS: m/z = 361 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{21}H_{16}N_2O_2S$ ; C, 69.98; H, 4.47; N, 7.77 %; found: C, 69.71; H, 4.38; N, 7.67 %.

#### *N*-(1-Ethyl-3-formyl-1*H*-indol-2-yl)thiophene-2-carboxamide (1f):

сно mp. 147-149 °C Ét

Pale yellow solid

IR (KBr): 3252, 3159, 2876, 1778, 1669, 1612, 1466, 752, 717 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 10.67 (s, 1H), 10.09 (s, 1H), 7.92-7.91 (m, 2H), 7.61 (d, 1H, J = 8.0 Hz), 7.39-7.37 (m, 1H), 7.31-7.13 (m, 3H), 4.30 (q, 2H, J = 8.0 Hz), 1.46 (t, 3H, J =8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 184.8, 160.8, 141.9, 137.5, 134.4, 134.1, 132.7, 130.9, 128.9, 125.4, 123.1, 123.0, 118.0, 110.8, 40.8, 14.1.

LC-MS: m/z = 299 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S; C, 64.41; H, 4.73; N, 9.39 %; found: C, 64.32; H, 4.79; N, 9.28 %.

#### *N*-(1-Butyl-3-formyl-1*H*-indol-2-yl)acetamide (1g):



Orange solid

mp. 176-178 °C

IR (KBr): 3259, 3160, 2852, 1776, 1670, 1635, 1532, 1479, 1452, 1382, 1210, 1120, 1020, 915, 720 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.99 (s, 1H), 9.61 (s, 1H), 8.02 (d, 1H, J = 8.0 Hz), 7.33-7.24 (m, 3H), 4.09 (t, 2H, J = 8.0 Hz), 2.28 (s, 3H), 1.79-1.71 (m, 2H), 1.33-1.25 (m, 2H), 0.91 (t, 3H, J = 8.0 Hz)

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 184.6, 170.5, 141.6, 134.3, 127.9, 124.8, 123.4, 123.0, 119.3, 110.7, 107.2, 44.4, 30.9, 20.1, 13.6.

LC-MS: m/z = 259 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{15}H_{18}N_2O_2$ ; C, 69.74; H, 7.02; N, 10.84 %; found: C, 69.85; H, 7.12; N, 10.76 %.

#### *N*-(1-Benzyl-3-formyl-1*H*-indol-2-yl)thiophene-2-carboxamide (1h) :



Yellow solid

mp. 229-231 °C IR (KBr): 3262, 3129, 2852, 1769, 1662, 1635, 1520, 1414, 1375, 1202, 1102, 1010, 919, 735 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 10.60 (s, 1H), 10.20 (s, 1H), 7.95 (d, 1H, J = 8.0 Hz), 7.83-7.82 (m, 1H), 7.65-7.63 (m, 1H), 7.31-7.24 (m, 6H), 7.18-7.15 (m, 1H), 7.09-7.07 (m, 2H), 5.62 (s, 2H).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 185.0, 160.6, 142.4, 137.3, 135.8, 134.9, 132.8, 131.2, 130.9, 128.8, 128.2, 127.9, 127.5, 126.7, 125.4, 123.2, 123.1, 117.5, 111.4, 105.2, 49.5. LC-MS: m/z = 361 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>21</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S; C, 69.98; H, 4.47; N, 7.77 %; found: C, 69.91; H, 4.52; N, 7.86 %.

# *N*-(3-Acetyl-1-ethyl-1*H*-indol-2-yl)nicotinamide (1i):



Dark brown solid

mp. 116-118 °C

 $\begin{array}{c} N \\ \dot{E}t \\ 1370, 1228, 1110, 1021, 915 \ \mathrm{cm}^{-1}. \end{array}$  IR (KBr): 3289, 3150, 2929, 2862, 1685, 1624, 1550, 1432, 1427,

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 11.78 (s, 1H), 9.33 (s, 1H), 8.82 (s, 1H), 8.40-8.38 (m, 1H), 7.82-7.79 (m, 1H), 7.48-7.43 (m, 2H), 7.31-7.29 (m, 2H), 4.35 (q, 2H, *J* = 8.0 Hz), 2.67 (s, 3H), 1.48 (t, 3H, *J* = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 195.8, 164.6, 153.2, 149.4, 142.5, 135.5, 134.3, 129.0, 124.9, 123.6, 122.7, 122.6, 120.0, 110.9, 104.3, 41.0, 30.6, 14.1.

LC-MS: m/z = 306 (M+H), negative mode; Anal. Calcd for molecular formula  $C_{18}H_{17}N_3O_2$ ; C, 70.34; H, 5.58; N, 13.67 %; found: C, 70.45; H, 5.51; N, 13.76 %.

#### *N*-(3-Acetyl-1-ethyl-1*H*-indol-2-yl)thiophene-2-carboxamide (1j):

Orange solid

mp. 132-134 °C

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 11.78 (s, 1H), 7.94 (d, 1H, J = 8.0 Hz), 7.82-7.80 (m, 1H), 7.64 (d, 1H, J = 8.0 Hz), 7.46-7.44 (m, 1H), 7.32-7.30 (m, 2H), 7.21-7.18 (m, 1H), 4.40 (q, 2H, J = 8.0 Hz), 2.70 (s, 3H), 1.50 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 195.7, 160.7, 143.1, 138.3, 134.4, 132.5, 130.7, 128.3, 125.0, 122.6, 122.4, 119.9, 110.9, 103.7, 41.2, 30.6, 14.1.

LC-MS: m/z = 313 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{17}H_{16}N_2O_2S$ ; C, 65.36; H, 5.16; N, 8.97 %; found: C, 65.26; H, 5.24; N, 8.91 %.

#### *N*-(3-Acetyl-1-hexyl-1*H*-indol-2-yl)acetamide (1k):



<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 10.46 (s, 1H), 7.82-7.80 (m, 1H), 7.39-7.38 (m, 1H), 7.30-7.27 (m, 2H), 4.24 (t, 2H, J = 8.0 Hz), 2.69 (s, 3H), 2.33 (s, 3H), 1.81-1.78 (m, 2H), 1.33-1.23 (m, 6H), 0.89-0.86 (m, 3H).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 195.4, 169.9, 142.3, 134.3, 124.9, 122.4, 122.2, 120.0, 110.9, 104.1, 45.6, 31.3, 30.7, 28.6, 26.5, 24.4, 22.5, 13.9.

LC-MS: m/z = 301 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{18}H_{24}N_2O_2$ ; C, 71.97; H, 8.05; N, 9.33 %; found: C, 71.85; H, 8.12; N, 9.45 %.

#### *N*-(3-Acetyl-1-benzyl-1*H*-indol-2-yl)acetamide (11):



Pale purple solid

mp. 223-225 °C

IR (KBr): 3252, 3232, 2910, 2855, 1672, 1634, 1575, 1556, 1477, 1329, 1125, 960, 907 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 10.45 (s, 1H), 7.85 (d, 1H, *J* = 8.0 Hz), 7.32-7.19 (m, 6H), 7.03-7.01 (m, 2H), 5.51 (s, 2H), 2.72 (s, 3H), 2.26 (s, 3H).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 195.5, 170.1, 142.5, 136.1, 134.7, 128.7, 128.1, 127.6, 126.7, 126.5, 124.8, 122.7, 122.5, 120.0, 111.3, 104.5, 49.1, 30.8, 24.3.

LC-MS: m/z = 307 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{19}H_{18}N_2O_2$ ; C, 74.49; H, 5.92; N, 9.14 %; found: C, 74.63; H, 5.88; N, 9.07 %.

## *N*-(3-acetyl-1-(phenylsulfonyl)-1*H*-indol-2-yl)nicotinamide (1m)(Known compound)



Solid, R<sub>f</sub> (8 % EtOAc/hexane)

mp: 171-172 °C

IR (KBr): 3352, 2961, 2926, 2856, 1726, 1668, 1614, 1460, 1373, 1248, 1099, 1043, 800, 744, 696 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 12.89 (s, 1H), 9.33 (s, 1H,), 8.85 (d, 1H, J = 8.0 Hz),

7.77-7.45 (m, 1H), 7.46-7.43 (m, 2H), 7.41-7.20 (m, 2H), 7.18-7.15 (m, 3H), 7.14-7.05 (m, 1H);

6.86-6.79 (m, 2H), 2.72 (s, 3H). Spectral data matched reported for this compound.

## *N*-(3-acetyl-1-(phenylsulfonyl)-1*H*-indol-2-yl)benzamide(1n): (Known compound)



Solid, R<sub>f</sub> (6 % EtOAc/hexane)

mp. 167-168 °C

IR (KBr): 3359, 2963, 2936, 2872, 1729, 1668, 1624, 1465, 1473, 1348, 1099, 1043, 810, 745, 699 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 12.81 (s, 1H), 8.11-8.09 (m, 1H), 7.80-7.69 (m, 1H), 7.67-7.60 (m, 2H), 7.58-7.55 (m, 2H), 7.44-7.35 (m, 2H), 7.32-7.27 (m, 4H), 7.26-7.14 (m, 2H), 2.75 (s, 3H). Spectral data matched reported for this compound.

# *N*-(3-acetyl-1-benzyl-1*H*-indol-2-yl)benzamide (10): (Known compound)



Solid,  $R_f$  (5 % EtOAc/Hexane) m.p. 217-218 °C

IR (KBr): 3295, 3157, 2991, 2962, 2872, 1689, 1614, 1545, 1462, 1417, 1373, 1271, 1228, 1155, 1107, 1022, 978, 914, 800, 746, 709 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 11.64 (s, 1H), 8.07-8.05 (m, 2H), 7.89-7.82 (m, 2H), 7.61-

7.54 (m, 1H), 7.52-7.40 (m, 2H), 7.36-7.34 (m, 1H), 7.26-7.24 (m, 4H), 7.09-7.07 (m, 2H), 5.66

(s, 2H), 2.75 (s, 3H). Spectral data matched reported for this compound

## *N*-(3-acetyl-1-hexyl-1*H*-indol-2-yl)nicotinamide (1p):

Solid,  $R_f$  (5 % EtOAc/hexane)



m.p. 271-272 °C

IR (KBr): 3057, 2959, 2928, 2866, 2247, 1689, 1614, 1554, 1419, 1271, 1228, 1155, 1107, 1022, 912, 748 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 11.80 (s, 1H), 9.37 (s, 1H), 8.86 (s, 1H), 8.42 (d, 1H, J = 4.0 Hz), 7.84-7.83 (m, 1H), 7.47-7.45 (m, 2H), 7.35-7.31 (m, 1H), 7.29-7.14 (m, 1H), 4.43 (q, 2H, J = 14.2 Hz), 2.70 (s, 3H), 1.29-1.23 (m, 9H), 0.91-0.78 (m, 2H). Spectral data matched reported for this compound.

## *N*-(3-acetyl-1-butyl-1*H*-indol-2-yl)benzamide(1q):



Solid, R<sub>f</sub> (4 % EtOAc/hexane)

m.p. 212-213 °C

<sup>*n*-Bu</sup> IR (KBr): 3271, 3057, 2961, 2930, 2866, 1685, 1614, 1548, 1462, 1417, 1373, 1271, 1228, 1155, 1107, 1022, 978, 914, 800, 746, 709 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 11.70 (s, 1H), 8.16-8.14 (m, 2H), 7.85-7.83 (m, 1H), 7.64-7.62 (m, 1H), 7.59-7.55 (m, 1H), 7.47-7.45 (m, 2H), 7.34-7.31 (m, 2H), 4.43 (t, 2H, J =

14.8 Hz), 2.75 (s, 3H), 1.85 (m, 2H), 1.33 (m, 2H), 0.93 (s, 3H). Spectral data matched reported<sup>3</sup> for this compound.

#### *N*-(3-acetyl-1-butyl-1*H*-indol-2-yl)thiophene-2-carboxamide (1r):



Solid,  $R_f$  (5 % EtOAc/hexane) m.p. 201-202 °C

 $\begin{array}{c} N & H & M \\ n-Bu & & \\ 1373, 1271, 1228, 1165, 1117, 1022, 978, 914, 800, 746, 718 \ \mathrm{cm}^{-1}. \end{array}$ 

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 11.83 (s, 1H), 7.96 (d, 1H, *J* = 4.0 Hz), 7.83-7.81 (m, 1H), 7.65-7.64 (m, 1H), 7.45-7.43 (m, 1H), 7.34-7.32 (m, 2H), 7.20-7.19 (m, 1H) 4.43-4.39 (m, 2H), 2.71 (s, 3H), 1.87-1.80 (m, 2H), 1.33-1.27 (m, 2H), 0.94 (t, 3H, *J* = 4.0 Hz). Spectral data matched reported<sup>3</sup> for this compound.

#### *N*-(3-acetyl-1-butyl-1*H*-indol-2-yl)acetamide (1s):

Solid,  $R_f$  (8 % EtOAc/hexane)

 $\begin{array}{c} & \text{m.p. } 102\text{-}103 \ ^{\circ}\text{C} \\ & \text{n-Bu} \\ & \text{IR (KBr): } 3059, \ 2959, \ 2930, \ 2866, \ 1689, \ 1616, \ 1554, \ 1462, \ 1419, \ 1269, \\ & 1155, \ 1107, \ 1020, \ 746 \ \text{cm}^{-1}. \end{array}$ 

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 10.48 (s, 1H), 7.82-7.80 (m, 1H), 7.42-7.39 (m, 1H), 7.32-7.28 (m, 2H), 4.26 (t, 2H, J = 14.8 Hz), 2.69 (s, 3H), 2.34 (s, 3H), 1.79 (q, 2H, J = 8.0 Hz), 1.28 (q, 2H, J = 8.0 Hz), 0.93 (s, 3H). Spectral data matched reported<sup>3</sup> for this compound.

## *N*-(3-acetyl-1-ethyl-1*H*-indol-2-yl)benzamide (1t):

Solid, R<sub>f</sub> (8 % EtOAc/hexane)

#### *N*-(3-acetyl-1-ethyl-1*H*-indol-2-yl)acetamide (1u): (Known compound)



<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 10.50 (s, 1H), 7.82-7.81 (m, 1H), 7.43-7.42 (m, 1H), 7.32-7.30 (m, 2H), 4.28 (q, 2H, J = 17.2 Hz), 2.69 (s, 3H), 2.34 (s, 3H), 1.46 (t, 3H, J = 4.2 Hz). Spectral data matched reported<sup>3</sup> for this compound.

#### 9-Ethyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2a)





mp. 117-119 °C

IR (KBr): 3429, 2927, 1658, 1026, 1003, 769, 725, 570, 528 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, DMSO-*d*<sub>6</sub>) δ: 10.88 (s, br, 1H), 7.94 (1H, d, J

= 6.16 Hz), 7.54 (d, 1H, *J* = 8.0 Hz), 7.36-7.33 (m, 1H), 7.20-7.17 (m, 1H), 6.29 (s, 1H), 4.40 (q, 2H, *J* = 5.68 Hz), 2.68 (s, 3H), 1.29 (t, 3H, *J* = 5.72 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, DMSO-*d*<sub>6</sub>) δ: 162.9, 149.5, 145.7, 137.6, 124.0, 121.7, 121.2, 120.0, 109.5, 106.8, 103.3, 36.0, 26.0, 14.3.

LC-MS: m/z = 225 (M+H), negative mode; Anal. Calcd for molecular formula C<sub>14</sub>H<sub>14</sub>N<sub>2</sub>O; C, 74.31; H, 6.24; N, 12.38 %; found: C,74.42; H, 6.21; N, 12.28 %.

#### 9-Ethyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2b)

Yellowish orange solid



mp. 152-154 °C IR (KBr): 3425, 2924, 1635, 1572, 1456, 1379, 1338, 1178, 1109,

 $1022, 750 \text{ cm}^{-1}.$ 

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 11.73 (s, br, 1H), 8.24 (d, 1H, J = 6.0 Hz), 8.11 (d, 2H, J = 6.0 Hz), 7.50-7.40 (m, 4H), 7.39-7.32 (m, 1H), 7.31-7.29 (m, 1H), 7.06 (s, 1H), 4.61 (q, 2H, J = 6.0 Hz); 1.52 (t, 3H, J = 5.6 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 159.3, 155.3, 153.5, 140.0, 138.6, 128.9, 128.6, 128.5, 128.0, 127.1, 125.2, 122.9, 120.0, 119.7, 108.6, 102.8, 100.3, 36.3, 14.1.

LC-MS: m/z = 289 (M+H), positive mode ; Anal. Calcd for molecular formula C<sub>19</sub>H<sub>16</sub>N<sub>2</sub>O; C, 79.14 ; H, 5.59; N, 9.72 %; found: C,79.24; H, 5.51; N, 9.65 %.

#### 9-Butyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2c)



IR (KBr): 3431, 2920, 1635, 1568, 1452, 1362, 1330, 1176, 1100, 1025, 756 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, DMSO- $d_6$ )  $\delta$ : 11.63 (s, br, 1H), 8.27 (d, 1H, J = 6.16 Hz), 8.00 (d,

2H, J = 4.0 Hz), 7.47-7.40 (m, 4H), 7.36 (d, 1H, J = 5.6 Hz), 7.31-7.28 (m, 1H), 6.98 (s, 1H),

4.53 (t, 2H, *J* = 8.0 Hz), 1.91-1.96 (m, 2H), 1.47-1.39 (m, 2H), 0.97 (t, 3H, *J* = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, DMSO-*d*<sub>6</sub>) δ: 160.2, 154.7, 153.4, 139.6, 138.8, 128.9, 128.6, 128.5,

128.0, 127.1, 125.1, 122.8, 120.0, 119.9, 108.9, 103.0, 100.8, 41.4, 31.1, 20.3, 13.8.

LC-MS: m/z = 317 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{21}H_{20}N_2O$ ; C,

79.72; H, 6.37; N, 8.85 %; found: C,79.61; H, 6.31; N, 8.79 %.

#### 9-Hexyl-2-(pyridin-3-yl)-9*H*-pyrido[2,3-*b*]indol-4-ol (2d)

Pale yellow solid,



тр. 112-113 °С

N N IR (KBr): 3412, 2918, 1572, 1458, 1375, 1340, 1170, 1109, 1024,  $c_{6}H_{13}$  771, 750, 694 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 10.59 (s, br, 1H), 8.45-8.10 (m, 2H), 7.59-7.13 (m, 7H), 4.48 (t, 2H, J = 4.0 Hz), 1.82 (t, 2H, J = 4.0 Hz), 1.32-1.12 (m, 6H), 0.75 (t, 3H, J = 8.0 Hz). <sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 161.0, 153.9, 138.8, 134.3, 133.0, 126.8, 125.8, 122.8, 121.4, 120.4, 120.2, 119.8, 119.7, 109.7, 103.0, 100.2, 41.1, 31.1, 28.6, 26.3, 22.4, 14.2. LC-MS: m/z = 346 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>O; C, 76.49; H, 6.71; N, 12.16 %; found: C, 76.38; H, 6.63; N, 12.23 %.

## 9-Benzyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2e)



IR (KBr): 3406, 2912, 1560, 1452, 1379, 1336, 1172, 1122, 1022,

770, 732, 654 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 10.88 (s, br, 1H), 7.95 (d, 1H, J = 7.68 Hz), 7.42 (d, 1H,

*J* = 7.68 Hz), 7.29-7.17 (m, 7H), 6.34 (s, 1H), 5.59 (s, 2H), 2.71 (s, 3H).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 163.0, 160.4, 150.2, 145.7, 138.1, 138.0, 128.8, 128.6,

127.5, 127.2, 124.1, 121.8, 121.2, 120.3, 110.0, 107.0, 103.5, 44.4, 20.1.

LC-MS: m/z = 289 (M+H), positive mode ; Anal. Calcd for molecular formula C<sub>19</sub>H<sub>16</sub>N<sub>2</sub>O; C,

79.14; H, 5.59; N, 9.72 %; found: C, 79.03; H, 5.51; N, 9.65 %.

#### 9-Hexyl-2-methyl-9H-pyrido[2,3-b]indol-4-ol (2f)



Pale yellow solid

mp. 122-124 °C IR (KBr): 3410, 2916, 2345, 2254, 2127, 1645, 1045, 1026, 997, 825, 761 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, DMSO- $d_6$ )  $\delta$ : 10.88 (s, br, 1H), 7.94 (d, 1H, J = 7.72 Hz), 7.53 (d, 1H, J = 7.72 Hz), 7.34 (t, 1H, J = 8.0 Hz), 7.18 (t, 1H, J = 8.0 Hz), 6.29 (s, 1H), 4.32 (t, 2H, J = 8.0 Hz), 2.68 (s, 3H), 1.75-1.72 (m, 2H), 1.24-1.20 (m, 6H), 0.80 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, DMSO-*d*<sub>6</sub>) δ: 162.9, 149.9, 145.6, 138.0, 124.0, 121.6, 121.1, 120.0, 109.7, 106.6, 103.5, 41.2, 31.4, 28.8, 26.4, 22.4, 20.1, 14.3.

LC-MS: m/z = 283 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{18}H_{22}N_2O$ ; C, 76.56; H, 7.85; N, 9.92 %; found: C, 76.45; H, 7.81; N, 9.88 %.

## 9-Butyl-2-methyl-9H-pyrido[2,3-b]indol-4-ol (2g)



IR (KBr): 3450, 2932, 1552, 1460, 1372, 1372, 1317, 1195, 1120,

1019, 779, 715 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, DMSO-*d*<sub>6</sub>) δ: 10.83 (s, br, 1H), 7.94 (d, 1H, *J* = 8.0 Hz), 7.55-7.52 (m, 1H), 7.35 (t, 1H, *J* = 8.0 Hz), 7.18 (t, 1H, *J* = 8.0 Hz), 6.28 (s, 1H), 4.32 (t, 2H, *J* = 8.0 Hz), 2.69 (s, 3H), 1.75-1.71 (m, 2H), 1.22-1.19 (m, 2H), 0.81 (t, 3H, *J* = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, DMSO-*d*<sub>6</sub>) δ: 163.2, 150.4, 146.1, 138.5, 124.2, 121.7, 121.0, 120.0,

110.0, 107.0, 103.3, 41.4, 31.5, 22.7, 20.3, 14.7.

LC-MS: m/z = 255 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>16</sub>H<sub>18</sub>N<sub>2</sub>O; C,

75.56; H, 7.13; N, 11.01 %; found: C, 75.46; H, 7.21; N, 11.12 %.

#### 9-Ethyl-2-(pyridin-3-yl)-9H-pyrido[2,3-b]indol-4-ol (2h)

mp. 122-124 °C



Pale yellow solid

IR (KBr): 3459, 2969, 1585, 1492, 1375, 1332, 1197, 1102, 1095,

785, 715 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 11.7 (s, br, 1H), 8.22 (d, 1H, J = 8.0 Hz), 8.13-8.08 (m, 2H), 7.47-7.43 (m, 3H), 7.39-7.37 (m, 1H), 7.28-7.26 (m, 1H), 7.04 (s, 1H), 4.59 (q, 2H, J = 8.0 Hz), 1.49 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 160.2, 155.7, 153.9, 140.0, 138.6, 128.9, 128.6, 128.1, 127.2, 125.3, 122.9, 120.1, 119.8, 108.7, 102.9, 100.4, 36.6, 13.8.

LC-MS: m/z = 290 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>18</sub>H<sub>15</sub>N<sub>3</sub>O; C, 75.69; H, 6.03; N, 13.24 %; found: C, 74.65; H, 5.28; N, 14.43 %.

#### 9-Butyl-2-(thiophen-2-yl)-9H-pyrido[2,3-b]indol-4-ol (2i)



<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 11.70 (s, br, 1H), 7.92-7.91 (m, 2H), 7.65-7.63 (m, 1H), 7.40-7.29 (m, 5H), 4.33 (t, 2H, J = 8.0 Hz), 1.85-1.78 (m, 2H), 1.28-1.26 (m, 2H), 0.90 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 160.5, 156.6, 149.5, 142.2, 137.5, 134.5, 132.7, 130.8, 128.3, 125.4, 123.1, 123.0, 117.7, 111.0, 105.2, 45.7, 30.8, 20.1, 13.6.

LC-MS: *m/z* = 323 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>OS; C, 70.78; H, 5.63; N, 8.69 %; found: C, 70.65; H, 5.58; N, 8.59 %.

#### 9-Benzyl-2-phenyl-9H-pyrido[2,3-b]indol-4-ol (2j)



Brown solid

mp. 128-130 °C

IR (KBr): 3452, 2927, 1572, 1445, 1372, 1327, 1190, 1130,

 $1052, 752, 711 \text{ cm}^{-1}.$ 

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 11.15 (s, br, 1H), 8.12 (d, 2H, *J* = 8.0 Hz), 7.57 (d, 1H, *J* = 8.0 Hz), 7.46-7.43 (m, 2H), 7.36 (d, 1H, *J* = 8.0 Hz), 7.20-7.13 (m, 6H), 6.99 (s, 1H), 6.75-6.72 (m, 1H), 6.59 (d, 1H, *J* = 8.0 Hz ), 4.86 (s, 2H).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 163.2, 160.4, 140.8, 136.1, 134.3, 134.1, 130.5, 130.4, 129.7, 129.0, 128.8, 128.7, 128.6, 128.4, 127.5, 127.3, 127.1, 123.6, 122.3, 122.2, 121.1, 116.8, 108.7, 43.5.

LC-MS: m/z = 351 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>24</sub>H<sub>18</sub>N<sub>2</sub>O; C, 82.26; H, 5.18; N, 7.99 %; found: C, 82.45; H, 5.23; N, 7.91 %.

### 4-Methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3a):

Yellow solid

H<sub>3</sub>C N N H

mp: 127-129 °C

IR (KBr): 3050, 2856, 1919, 1852, 1680, 1570, 1462, 1252, 1170, 1100,

1028, 990, 752 cm<sup>-1</sup>

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 11.0 (s, 1H,), 7.89-7.88 (m, 1H), 7.78-7.70 (m, 1H), 7.69-7.29 (m, 3H), 7.24-7.21 (m, 2H,), 2.73 (s, 3H).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 161.8, 158.4, 144.4, 137.2, 133.0, 132.3, 130.7, 128.4,
123.7, 122.7, 122.3, 119.3, 111.8, 101.0, 29.9.

LC-MS: m/z = 265 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>S;

C, 67.90; H, 4.18; N, 15.84 %; found: C, 67.81; H, 4.23; N. 15.76 %.

## 9-Butyl-2,4-dimethyl-9*H*-pyrimido[4,5-*b*]indole(3b)

Pale purple solid or Pink



mp: 117-119 °C

IR (KBr): 3059, 2926, 2856, 1923, 1886, 1682, 1622, 1574, 1494, 1469, 1408, 1255, 1174, 1111, 1028, 999, 927, 794, 736 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 8.07 (d, 1H, *J* = 8.0 Hz), 7.53-7.50 (m, 2H), 7.35-7.26 (m, 1H), 4.43 (t, 2H, *J* = 8.0 Hz), 2.95 (s, 3H), 2.82 (s, 3H), 1.89-1.85 (m, 2H), 1.41-1.35 (m, 2H), 0.96 (t, 3H, *J* = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 163.7, 159.2, 155.8, 139.0, 126.3, 122.5, 120.9, 120.2, 109.7, 109.5, 41.1, 30.8, 29.7, 26.4, 20.2, 13.7.
LC-MS: m/z = 254 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{16}H_{19}N_3$ ; C, 75.85; H, 7.56; N, 16.59 %; found: C, 75.96; H, 7.52; N, 16.51 %.

#### 9-Butyl-4-methyl-2-phenyl-9*H*-pyrimido[4,5-*b*]indole (3c)



<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 8.64 (d, 2H, J = 8.0 Hz), 8.11 (d, 1H, J = 8.0 Hz), 7.55-7.35 (m, 6H), 4.55 (t, 2H, J = 8.0 Hz), 3.08 (s, 3H,), 2.32-2.29 (m, 2H), 1.96-1.92 (m, 2H), 0.99 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 160.3, 159.4, 145.7, 144.2, 139.7, 130.1, 128.4, 126.7, 122.7, 121.2, 120.2, 118.2, 114.8, 112.7, 110.4, 109.7, 41.2, 31.9, 29.7, 20.2, 14.1.

LC-MS: m/z = 316 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{21}H_{21}N_3$ ; C, 79.97; H, 6.71; N, 13.32 %; found: C, 79.85; H, 6.81; N, 13.45 %.

#### 9-Butyl-4-methyl-2-(pyridin-3-yl)-9*H*-pyrimido[4,5-*b*]indole (3d):



<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.82 (s, 1H), 8.87-8.84 (m, 1H), 8.69 (s, 1H), 8.07 (d, 1H, J = 8.0 Hz), 7.57-7.49 (m, 2H), 7.44-7.35 (m, 2H), 4.49 (t, 2H, J = 4.0 Hz), 3.01 (s, 3H), 1.95-1.87 (m, 2H), 1.45-1.34 (m, 2H), 0.99 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 159.7, 158.0, 155.6, 150.3, 149.9, 139.5, 135.5, 134.3,
126.8, 123.2, 122.7, 121.1, 120.0, 110.9, 109.7, 41.2, 30.8, 23.1, 20.2, 13.7.
LC-MS: m/z = 317 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>;
C, 75.92; H, 6.37; N, 17.71 %; found: C, 75.85; H, 6.31; N, 17.65 %.

#### 9-Butyl-4-methyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-b]indole (3e):



Brown colour solid

mp: 131-133 °C

IR (KBr): 2926, 2858, 1620, 1572, 1531, 1494, 1469, 1400, 1263, 1097, 848, 798, 718 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) *δ*: 8.13-8.08 (m, 2H), 7.57-7.46 (m, 3H), 7.39-3.28 (m, 1H), 7.19-7.17 (m, 1H), 4.51 (t, 2H, *J* = 8.0 Hz), 3.02 (s, 3H), 1.91-1.90 (m, 2H), 1.44-1.38 (m, 2H), 1.13 (t, 3H, *J* = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 159.7, 157.1, 155.6, 144.9, 139.4, 128.7, 128.1, 128.0, 126.4, 122.5, 121.0, 120.4, 110.1, 109.7, 41.0, 30.7, 23.0, 20.1, 13.7.

LC-MS: m/z = 322 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>S; C, 70.99; H, 5.96; N, 13.07 %; found: C, 70.85; H, 5.91; N, 13.18 %.

#### 9-Hexyl-2,4-dimethyl-9*H*-pyrimido[4,5-*b*]indole (3f)



Yellow solid

mp: 102-103 °C

IR (KBr): 3049, 2930, 2866, 1930, 1682, 1622, 1574, 1496, 1469, 1402, 1205, 1018, 993, 823, 792, 742, 711, 435 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 8.05 (d, 1H, *J* = 8.0 Hz), 7.53-7.47 (m, 2H), 7.37-7.33 (m, 1H), 4.41 (t, 2H, *J* = 4.0 Hz), 2.97 (s, 3H), 2.82 (s, 3H), 1.88-1.85 (m, 2H), 1.34-1.26 (m, 6H), 0.86 (t, 3H, *J* = 4.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 163.5, 159.0, 155.6, 139.6, 126.4, 122.5, 121.0, 120.1, 109.7, 41.3, 31.4, 29.7, 28.6, 26.6, 26.1, 22.6, 22.5, 14.0.

LC-MS: m/z = 282 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{18}H_{23}N_3$ ; C, 76.83; H, 8.24; N, 14.93 %; found: C, 76.65; H, 8.19; N, 14.85 %.

#### 9-Ethyl-4-methyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-b]indole (3g):



Off-white solid

mp: 122-124 °C

<sup>S</sup><sup>-1</sup> IR (KBr): 2950, 2892, 1526, 1452, 1398, 1256, 1166, 1112, 1035, 856,

795, 722  $\text{cm}^{-1}$ .

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 8.07-8.05 (m, 2H), 7.55-7.50 (m, 2H), 7.48-7.14 (m, 3H),

4.51 (q, 2H, *J* = 8.0 Hz), 2.98 (s, 3H), 1.49 (t, 3H, *J* = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 159.8, 157.2, 155.2, 144.8, 139.1, 131.6, 128.7, 128.0, 126.4, 122.5, 121.1, 120.6, 110.4, 109.6, 36.3, 29.7, 14.0.

LC-MS: m/z = 294 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{17}H_{15}N_3S$ ; C, 69.59; H, 5.15; N, 14.32 %; found: C, 69.45; H, 5.21; N, 14.25 %.

#### 9-Benzyl-4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3h)



IR (KBr): 2924, 2858, 1570, 1494, 1427, 1398, 1249, 1163, 1151, 1101, 1093, 1020, 844, 796, 711 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 8.15-8.07 (m, 2H), 7.47-7.17 (m, 10H), 5.70 (s, 2H), 3.04 (s, 3H).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 160.0, 157.3, 155.7, 144.7, 139.3, 138.2, 136.7, 128.9, 128.7, 128.5, 128.2, 128.0, 127.9, 127.6, 126.5, 123.2, 122.4, 122.2, 121.4, 120.6, 110.2, 45.1. LC-MS: m/z = 356 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>22</sub>H<sub>17</sub>N<sub>3</sub>S; C, 74.34; H, 4.82; N, 11.82 %; found: C, 74.19; H, 4.78; N, 11.75 %.

#### 9-Hexyl-4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3i)



light yellow solid

mp: 129-131°C

IR (KBr): 3020, 2950, 2828, 1522, 1454, 1422, 1362, 1207, 1160, 1109,1052, 1032, 850, 752 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 8.89-8.71 (m, 1H), 8.14-8.13 (m, 1H), 7.61-7.28 (m, 5H), 4.63-4.40 (m, 2H), 2.87 (s, 3H), 1.55 -1.46 (m, 5H), 1.31-1.26 (m, 4H), 0.91-0.86 (m, 2H). <sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 159.8, 158.2, 155.3, 153.3, 150.5, 150.1, 149.6, 139.2,

135.6, 126.8, 122.8, 121.2, 111.1, 109.6, 41.1, 36.3, 31.6, 30.5, 29.6, 23.1, 13.9.

LC-MS: m/z = 350 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>S; C,

72.17; H, 6.63; N, 12.02 %; found: C, 72.08; H, 6.69; N, 12.15 %.

#### 9-Butyl-2-(pyridin-3-yl)-9H-pyrimido[4,5-b]indole (3j)



IR (KBr): 3059, 2922, 2852, 1612, 1573, 1459, 1400, 1252, 1160, 1121, 1020, 795, 738 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.83 (s, 1H), 9.34 (s, 1H), 8.87-8.72 (m, 2H), 8.15 (d, 1H, J = 8.0 Hz), 7.60-7.58 (m, 1H), 7.55-7.53 (m, 1H), 7.47-7.44 (m, 1H), 7.41-7.37 (m, 1H), 4.55 (t, 2H, J = 8.0 Hz), 1.99-1.92 (m, 2H), 1.48-1.39 (m, 2H), 1.01 (t, 3H, J = 8.0 Hz). <sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 158.7, 155.6, 150.6, 150.0, 148.0, 139.9, 135.5, 134.2,

127.6, 123.4, 121.5, 121.3, 119.2, 112.9, 110.0, 41.2, 30.8, 20.1, 13.7.

LC-MS: *m/z* = 303 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>; C, 75.47; H, 6.00; N, 18.53 %; found: C,75.54; H, 6.08; N, 18.41 %.

#### 9-Ethyl-2-phenyl-9*H*-pyrimido[4,5-*b*]indole (3k)

Greenish brown solid



тр. 114-116 °С

Et 1433, 1400, 1359, 1224, 1140, 1091, 1066, 1024, 993, 923, 810, 769, 738, 698, 543, 449, 405 cm<sup>-1</sup>.

IR (KBr): 3061, 2978, 2930, 1668, 1622, 1581, 1556, 1493, 1467,

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) *δ*: 9.33 (s, 1H), 8.65 (m, 2H), 8.13 (d, 1H, *J* = 7.8 Hz), 7.58-7.50 (m, 5H), 7.39-7.35 (m, 1H), 4.59 (q, 2H, *J* = 7.2 Hz), 1.54 (t, 3H, *J* = 7.24 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 160.8, 155.4, 148.0, 139.5, 138.7, 132.0, 130.1, 129.2, 128.4, 128.3, 127.3, 121.4, 121.1, 119.5, 112.5, 109.6, 36.2, 13.9.

LC-MS: *m/z* = 275 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>18</sub>H<sub>15</sub>N<sub>3</sub>; C, 79.10; H, 5.53; N, 15.53 %; found: C, 79.21; H, 5.58; N, 15.58 %.

#### 9-Ethyl-2-(pyridin-3-yl)-9*H*-pyrimido[4,5-*b*]indole (3l)



Yellowish orange solid

mp. 92-94 °C

IR (KBr): 3042, 2935, 2920, 1610, 1562, 1552, 1530, 1485, 1475, 1390, 1200, 1132, 1085, 850, 795, 732, 709, 415 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.79 (s, 1H), 9.27 (d, 1H, J = 2.0 Hz), 8.81 (d, 1H, J = 7.84

Hz), 8.68 (s, 1H), 8.08 (d, 1H, J = 7.64 Hz), 7.54 (d, 1H, J = 7.32 Hz), 7.49-7.47 (m, 1H), 7.42-

7.39 (m, 1H), 7.36-7.32 (m, 1H), 4.53 (q, 2H, J = 4.0 Hz), 1.50 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 158.6, 155.1, 149.9, 147.9, 139.5, 135.5, 134.1, 132.8,

123.3, 121.5, 121.3, 119.2, 113.0, 109.7, 108.2, 36.3, 13.9.

LC-MS: m/z = 275 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{17}H_{14}N_4$ ; C,

74.43; H, 5.14; N, 20.42 %; found: C, 74.32; H, 5.21; N, 20.36 %.

#### 9-Ethyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3m)



IR (KBr): 3053, 2974, 2928, 1622, 1585, 1554, 1531, 1493, 1469,

1429, 1396, 1221, 1138, 1084, 852, 796, 738, 709, 451, 405 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 9.21 (s, 1H), 8.14-8.08 (m, 2H), 7.58-7.47 (m, 3H), 7.37-

7.33 (m, 1H), 7.20-7.18 (m, 1H), 4.54 (q, 2H, J = 7.2 Hz), 1.52 (t, 3H, J = 7.24 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 157.6, 155.1, 147.9, 144.7, 139.4, 128.9, 128.7, 128.2, 128.1, 127.2, 121.2, 119.6, 112.2, 109.6, 36.2, 13.9.

LC-MS: m/z = 280 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>16</sub>H<sub>13</sub>N<sub>3</sub>S; C, 68.79; H, 4.69; N, 15.04 %; found: C, 68.85; H, 4.61; N, 15.11 %.

#### 9-Benzyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole(3n)



Pale brown Solid

mp. 92-94 °C

IR (KBr): 3120, 2960, 2952, 1610, 1530, 1512, 1490, 1452, 1350, 1220, 1150, 1082, 847, 752 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 9.25 (s, 1H), 8.15-8.14 (m, 1H), 8.09 (d, 1H, *J* = 7.76 Hz); 7.50-7.46 (m, 2H); 7.42-7.36 (m, 3H), 7.34-7.32 (m, 2H), 7.30-7.25 (m, 2H), 7.20-7.18 (m, 1H),

5.69 (s, 2H).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 157.8, 155.7, 148.1, 144.5, 139.6, 136.5, 131.7, 129.1, 128.8, 128.3, 128.2, 127.7, 127.5, 127.4, 126.4, 121.6, 121.2, 119.7, 112.2, 110.4, 45.1.

LC-MS: m/z = 342 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>21</sub>H<sub>15</sub>N<sub>3</sub>S; C, 73.87; H, 4.43; N, 12.31 %; found: C, 73.96; H, 4.38; N, 12.45 %.

# 5-Butyl-2-methyl-5*H*-pyrimido[5,4-*b*]indole (30)



*n*-Bu IR (KBr): 3050, 2922, 1612, 1525, 1517, 1460, 1412, 1360, 1222, 1166, 1022, 867, 717 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.13 (s, 1H), 8.06 (d, 1H, J = 8.0 Hz); 7.53-7.51 (m, 1H), 7.47-7.45 (m, 1H), 7.34-7.32 (m, 1H), 4.41 (t, 2H, J = 8.0 Hz), 2.8 (s, 3H), 1.88-1.84 (m, 2H), 1.40-1.35 (m, 2H), 0.96 (t, 3H, J = 4.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 164.2, 155.7, 147.6, 139.3, 127.1, 121.1, 121.0, 119.3, 111.5, 109.8, 41.1, 30.8, 26.4, 20.2, 13.7.

LC-MS: m/z = 240 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>15</sub>H<sub>17</sub>N<sub>3</sub>; C,75.28 ; H, 7.16; N, 17.56 %; found: C, 75.36; H, 7.21; N, 17.45 %.

#### 5-Butyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole (3p)



<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.33 (s, 1H), 8.62-8.60 (m, 2H), 8.11 (d, 1H, J = 7.72 Hz), 7.55-7.44 (m, 5H) 7.37-7.33 (m, 1H), 4.53 (t, 2H, J = 7.04 Hz), 1.97-1.89 (m, 2H), 1.45-1.35 (m, 2H), 0.98 (t, 3H, J = 7.32 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 160.5, 155.9, 147.6, 139.9, 138.3, 137.3, 135.2, 130.2, 128.5, 128.3, 127.4, 121.4, 121.2, 119.4, 112.3, 109.9, 41.2, 30.8, 20.2, 13.7.

LC-MS: m/z = 302 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{20}H_{19}N_3$ ; C, 79.70; H, 6.35; N, 13.94 %; found: C, 79.86; H, 6.31; N, 13.81 %.

#### 5-Ethyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole (3q)



Pale brown solid

mp. 133-135 °C

IR (KBr): 3046, 2992, 1655, 1585, 1575, 1462, 1417, 1379, 1235, 1216, 859, 792, 717 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.36 (s, 1H), 8.61-8.58 (m, 2H), 8.14-8.12 (m, 1H), 7.61-7.50 (m, 5H), 7.40-7.36 (m, 1H), 4.60 (q, 2H, *J* = 8.0 Hz), 1.54 (t, 3H, *J* = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 160.3, 155.0, 147.1, 139.7, 137.8, 130.4, 128.6, 128.3,

127.7, 121.6, 121.5, 119.4, 116.9, 114.7, 112.5, 109.8, 36.4, 13.9.

LC-MS: m/z = 274 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>18</sub>H<sub>15</sub>N<sub>3</sub>; C,

79.10; H, 5.53; N, 15.37 %; found: C, 79.25; H, 5.61; N, 15.26 %.

#### 5-Ethyl-2-(thiophen-2-yl)-5*H*-pyrimido[5,4-*b*]indole (3r)



Yellow solid

mp. 129-131 °C

IR (KBr): 2950, 2822, 1652, 1621, 1582, 1557, 1492, 1443, 1372, 1236, 1217, 892, 819, 792, 712cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 9.23 (s, 1H), 8.14-8.13 (m, 1H), 8.09 (d, 1H, J = 8.0 Hz), 7.58-7.47 (m, 3H), 7.37-7.34 (m, 1H), 7.20-7.18 (m, 1H), 4.53 (q, 2H, J = 8.0 Hz), 1.52 (t, 3H, J = 8.0 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 158.1, 155.5, 148.4, 145.1, 139.6, 139.3, 129.3, 129.1,
128.2, 127.3, 121.4, 119.7, 112.4, 109.8, 36.3, 14.1.

LC-MS: m/z = 280 (M+H), positive mode; Anal. Calcd for molecular formula C<sub>16</sub>H<sub>13</sub>N<sub>3</sub>S; C,

68.79; H, 4.69; N, 15.04 %; found: C, 68.62; H, 4.61; N, 15.16 %.

#### 5-Butyl-2-(pyridin-3-yl)-5*H*-pyrimido[5,4-*b*]indole (3s)



White dirty solid

mp. 132-134 °C

IR (KBr): 2962, 2810, 1662, 1600, 1572, 1523, 1485, 1432, 1379, 1252, 1227, 891, 822, 779, 720cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) δ: 9.31 (s, 1H), 8.85 (d, 2H, *J* = 8.0 Hz), 8.12 (d, 1H, *J* = 7.76 Hz), 7.60-7.50 (m, 2H), 7.45-7.34 (m, 3H), 4.52 (t, 2H, *J* = 7.04 Hz), 1.97-1.90 (m, 2H), 1.46-1.36 (m, 2H), 0.99 (t, 3H, *J* = 7.04 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 164.0, 158.4, 155.6, 150.4, 149.8, 148.0, 139.9, 135.6, 132.6, 122.7, 121.5, 121.3, 119.2, 112.9, 110.0, 41.2, 30.8, 20.2, 13.7.

LC-MS: m/z = 303 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{19}H_{18}N_4$ ; C, 75.47; H, 6.00; N, 18.53 %; found: C, 75.38; H, 6.12; N, 18.45 %.

#### 5-Butyl-2-(thiophen-2-yl)-5*H*-pyrimido[5,4-*b*]indole (3t)

Purple brown solid



mp. 119-121 °C

IR (KBr): 3012, 2912, 1672, 1612, 1880, 1532, 1480, 1462, 1395, 1386, 1332, 1289, 1252, 1212, 1192, 896, 852, 779, 715cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) $\delta$ : 9.23 (s, 1H), 8.13-8.09 (m, 2H), 7.58-7.47 (m, 3H), 7.38-7.34 (m, 1H), 7.28-7.18 (m, 1H), 4.51 (t, 2H, *J* = 4.0 Hz), 1.98-1.91 (m, 2H), 1.46-1.37 (m, 2H), 1.02 (t, 3H, *J* = 7.32 Hz).

<sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 157.5, 155.6, 147.9, 144.7, 139.8, 129.0, 128.1, 128.0, 127.2, 121.3, 121.2, 119.6, 112.0, 109.9, 41.1, 30.7, 20.1, 13.6.

LC-MS: m/z = 306 (M-H), negative mode; Anal. Calcd for molecular formula C<sub>18</sub>H<sub>17</sub>N<sub>3</sub>S; C, 75.47; H, 5.57; N, 13.67 %; found: C, 70.25; H, 5.51; N, 13.76 %.

#### (9-ethyl-3-nitro-2-phenyl-2,9-dihydro-1H-pyrido[2,3-b]indol-1-

#### yl)(phenyl)methanone (4a)



Pale yellow solid

mp. 232-234 °C

IR (KBr): 3063, 2926, 2854, 1670, 1612, 1508, 1464, 1352, 1269, 1095, 1018, 750, 690 cm<sup>-1</sup>.

<sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>) *δ*: 8.61 (s, 1H), 7.76-7.74 (m, 1H), 7.53-7.52 (m, 4H), 7.40-7.35 (m, 4H), 7.32-7.19 (m, 5H), 7.16 (s, 1H), 3.63 (q, 2H, *J* = 4.0 Hz), 0.91 (t, 3H, *J* = 7.32 Hz). <sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 169.7, 149.3, 139.6, 137.1, 136.4, 135.8, 133.1, 132.1,
128.9, 128.8, 128.7, 128.5, 127.1, 126.9, 126.6, 124.0, 123.4, 122.7, 118.6, 117.2, 112.4, 111.0,
102.1, 58.3, 39.6, 13.6.

LC-MS: m/z = 424 (M+H), positive mode; Anal. Calcd for molecular formula  $C_{26}H_{21}N_3O_3$ ; C, 73.74; H, 5.00; N, 9.92 %; found: C,73.65; H,5.00; N, 9.98 %.

#### (9- Ethyl-3-nitro-2-phenyl-2, 9-dihydro-1 H-pyrido [2, 3-b] indol-1-yl) (thiophen-2-phenyl-2, 9-dihydro-1 H-pyrido [2, 3-b]

#### yl)methanone (4b)

Orange solid



mp. 217-219 °C

IR (KBr): 2916, 1651, 1612, 1527, 1509, 1432, 1272, 1105, 1018 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, TMS, CDCl<sub>3</sub>)  $\delta$ : 8.60 (s, 1H), 7.75-7.74 (m, 1H), 7.58-7.57 (m, 1H), 7.38-7.37 (m, 1H), 7.32-7.30 (m, 2H), 7.29-7.26 (m,

6H), 7.25-7.05 (m, 1H), 6.95-6.93 (m, 1H), 3.69 (q, 2H, *J* = 4.0 Hz), 0.87 (t, 3H, *J* = 4.0 Hz). <sup>13</sup>C NMR (100 MHz, TMS, CDCl<sub>3</sub>) δ: 162.7, 138.6, 137.4, 136.2, 135.8, 135.7, 135.5, 133.4, 133.3, 132.6, 128.8, 127.8, 127.1, 126.7, 126.4, 123.9, 123.6, 122.7, 118.7, 111.0, 102.5, 58.3, 39.5, 13.6.

LC-MS: m/z = 428 (M-H), negitive mode; Anal. Calcd for molecular formula  $C_{24}H_{19}N_3O_3S$ ; C, 67.12; H, 4.46; N, 9.78 %; found: C, 67.26; H, 4.51; N, 9.65 %.





<sup>13</sup>C NMR of *N*-(1-ethyl-2-formyl-1*H*-indol-3-yl)benzamide (1a):



#### LCMS of *N*-(1-ethyl-2-formyl-1*H*-indol-3-yl)benzamide (1a):



#### CHN Analysis of N-(1-ethyl-2-formyl-1H-indol-3-yl)benzamide (1a):



## <sup>1</sup>H NMR of *N*-(1-butyl-2-formyl-1*H*-indol-3-yl)nicotinamide (1b):



# <sup>13</sup>C NMR of *N*-(1-butyl-2-formyl-1*H*-indol-3-yl)nicotinamide (1b):





**DEPT of** *N*-(1-butyl-2-formyl-1*H*-indol-3-yl)nicotinamide (1b):

#### LCMS of *N*-(1-butyl-2-formyl-1*H*-indol-3-yl)nicotinamide (1b):



#### CHN Analysis of N-(1-butyl-2-formyl-1H-indol-3-yl)nicotinamide (1b):



### <sup>1</sup>H NMR of *N*-(1-butyl-2-formyl-1*H*-indol-3-yl)acetamide (1c):







#### LCMS of *N*-(1-butyl-2-formyl-1*H*-indol-3-yl)acetamide (1c):



#### CHN Analysis of N-(1-butyl-2-formyl-1H-indol-3-yl)acetamide (1c):





<sup>1</sup>H NMR of *N*-(1-butyl-2-formyl-1*H*-indol-3-yl)thiophene-2-carboxamide (1d):



# <sup>13</sup>C NMR of *N*-(1-butyl-2-formyl-1*H*-indol-3-yl)thiophene-2-carboxamide (1d):



#### LCMS of N-(1-butyl-2-formyl-1H-indol-3-yl)thiophene-2-carboxamide (1d):



#### CHN of *N*-(1-butyl-2-formyl-1*H*-indol-3-yl)thiophene-2-carboxamide (1d):



# <sup>1</sup>H NMR of *N*-(1-benzyl-2-formyl-1*H*-indol-3-yl)thiophene-2-carboxamide





# <sup>13</sup>C NMR of *N*-(1-benzyl-2-formyl-1*H*-indol-3-yl)thiophene-2-carboxamide

(1e):



#### LCMS of N-(1-benzyl-2-formyl-1H-indol-3-yl)thiophene-2-carboxamide (1e):



#### CHN Analysis of N-(1-benzyl-2-formyl-1H-indol-3-yl)thiophene-2-

#### carboxamide (1e):



<sup>1</sup>H NMR of *N*-(1-ethyl-3-formyl-1*H*-indol-2-yl)thiophene-2-carboxamide (1f):



# <sup>13</sup>C NMR of *N*-(1-ethyl-3-formyl-1*H*-indol-2-yl)thiophene-2-carboxamide (1f):



#### LCMS of N-(1-ethyl-3-formyl-1H-indol-2-yl)thiophene-2-carboxamide (1f):



# CHN Analysis of *N*-(1-ethyl-3-formyl-1*H*-indol-2-yl)thiophene-2-carboxamide (1f):


### <sup>1</sup>H NMR of *N*-(1-butyl-3-formyl-1*H*-indol-2-yl)acetamide (1g):



## <sup>13</sup>C NMR of *N*-(1-butyl-3-formyl-1*H*-indol-2-yl)acetamide (1g):



#### **DEPT of** *N*-(1-butyl-3-formyl-1*H*-indol-2-yl)acetamide (1g):



#### LCMS of *N*-(1-butyl-3-formyl-1*H*-indol-2-yl)acetamide (1g):



#### CHN Analysis of *N*-(1-butyl-3-formyl-1*H*-indol-2-yl)acetamide (1g):



# <sup>1</sup>H NMR of *N*-(1-benzyl-3-formyl-1*H*-indol-2-yl)thiophene-2-carboxamide

#### (1h):



# <sup>13</sup>C NMR of *N*-(1-benzyl-3-formyl-1*H*-indol-2-yl)thiophene-2-carboxamide(1h):



#### LCMS of N-(1-benzyl-3-formyl-1H-indol-2-yl)thiophene-2-carboxamide (1h):



#### CHN Analysis of N-(1-benzyl-3-formyl-1H-indol-2-yl)thiophene-2-

#### carboxamide (1h):



#### <sup>1</sup>H NMR of *N*-(3-acetyl-1-ethyl-1*H*-indol-2-yl)nicotinamide (1i):



# <sup>13</sup>C NMR of *N*-(3-acetyl-1-ethyl-1*H*-indol-2-yl)nicotinamide (1i):



#### LCMS of *N*-(3-acetyl-1-ethyl-1*H*-indol-2-yl)nicotinamide (1i):



#### CHN Analysis of *N*-(3-acetyl-1-ethyl-1*H*-indol-2-yl)nicotinamide (1i):



### <sup>1</sup>H NMR of *N*-(3-acetyl-1-ethyl-1*H*-indol-2-yl)thiophene-2-carboxamide (1j):







#### DEPT of N-(3-acetyl-1-ethyl-1H-indol-2-yl)thiophene-2-carboxamide (1j):



#### LCMS of N-(3-acetyl-1-ethyl-1H-indol-2-yl)thiophene-2-carboxamide (1j):



# CHN Analysis of N-(3-acetyl-1-ethyl-1H-indol-2-yl)thiophene-2-carboxamide

#### (**1j**):



<sup>1</sup>H NMR of *N*-(3-acetyl-1-hexyl-1*H*-indol-2-yl)acetamide (1k):



<sup>13</sup>C NMR of *N*-(3-acetyl-1-hexyl-1*H*-indol-2-yl)acetamide (1k):



#### LCMS of *N*-(3-acetyl-1-hexyl-1*H*-indol-2-yl)acetamide (1k):



#### CHN Analysis of *N*-(3-acetyl-1-hexyl-1*H*-indol-2-yl)acetamide (1k):



<sup>1</sup>H NMR of *N*-(3-acetyl-1-benzyl-1*H*-indol-2-yl)acetamide (11):



<sup>13</sup>C NMR of *N*-(3-acetyl-1-benzyl-1*H*-indol-2-yl)acetamide (11):



DEPT of N-(3-acetyl-1-benzyl-1H-indol-2-yl)acetamide (11):



#### LCMS of *N*-(3-acetyl-1-benzyl-1*H*-indol-2-yl)acetamide (11):



#### CHN Analysis of N-(3-acetyl-1-benzyl-1H-indol-2-yl)acetamide (11):



#### <sup>1</sup>H NMR of 9-ethyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2a):



<sup>13</sup>C NMR of 9-ethyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2a)



DEPT of 9-ethyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2a)



#### LCMS 9-ethyl-2-methyl-9H-pyrido[2,3-b]indol-4-ol (2a)

#### **LCMS-2010A DATA REPORT** SCHOOL OF CHEMISTRY UNIVERSITY OF HYDERABAD HO k $CH_3$ : Admin User : ASK-C2 Sample T : 5.000 Inj. Volume Et : C:\LCMSsolution\User\Data\ASK-C2-APCI-NEG1.qld Data Name : C:\LCMSsolution\User\Method\esi.qlm Method Name LC Chromatogram mAbs Ch1(254.0nm)\*1.00 300 250 200 150 100 50 0 min MS Spectrum Line#:1 R.Time:0.802(Sean#:48) Negative MassPeaks:159 BasePeak:225.10(245679) RawMode:Single 0.802(48) BG Mode:Peak Start 0.560(34) 100-225 289 295 257 223 239 271 196 205 119 134 146 159 182 81 98 104 52 260 270 280 290 240 250 190 200 210 230 50 70 80 90 100 110 120 130 140 150 160 170 180 220 60 m/z MS Peak Table Base m/z Base Int. 225.10 245679 1.Time F.Time 0.560 1.143 A/H Mark %Total Name Height 2284097 Peak# R.Time 1 0.802 Area 100.00 34385003 15.05 34385003 2284097

S103

**OPERATOR** 

#### CHN Analysis of 9-ethyl-2-methyl-9H-pyrido[2,3-b]indol-4-ol (2a)



<sup>1</sup>H NMR of 9-ethyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2b)



#### <sup>13</sup>C NMR of 9-ethyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2b)



DEPT of 9-ethyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2b)



#### LCMS of 9-ethyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2b)


# CHN Analysis of 9-ethyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2b)



<sup>1</sup>H NMR of 9-butyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2c)



<sup>13</sup>C NMR of 9-butyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2c)



DEPT of 9-butyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2c)



#### LCMS of 9-butyl-2-phenyl-9H-pyrido[2,3-b]indol-4-ol (2c)



#### CHN Analysis of 9-butyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2c)



<sup>1</sup>H NMR of 9-hexyl-2-(pyridin-3-yl)-9*H*-pyrido[2,3-*b*]indol-4-ol (2d)



<sup>13</sup>C NMR of 9-hexyl-2-(pyridin-3-yl)-9*H*-pyrido[2,3-*b*]indol-4-ol (2d)



DEPT of 9-hexyl-2-(pyridin-3-yl)-9*H*-pyrido[2,3-*b*]indol-4-ol (2d)



## LCMS of 9-hexyl-2-(pyridin-3-yl)-9*H*-pyrido[2,3-*b*]indol-4-ol (2d)



### CHN Analysis of 9-hexyl-2-(pyridin-3-yl)-9H-pyrido[2,3-b]indol-4-ol (2d)



<sup>1</sup>H NMR of 9-benzyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2e)







#### LCMS of 9-benzyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2e)



#### CHN Analysis of 9-benzyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2e)



<sup>1</sup>H NMR of 9-hexyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2f)







DEPT of 9-hexyl-2-methyl-9H-pyrido[2,3-b]indol-4-ol (2f)







### CHN Analysis of 9-hexyl-2-methyl-9H-pyrido[2,3-b]indol-4-ol (2f)



<sup>1</sup>H NMR of 9-butyl-2-methyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2g)







#### LCMS of 9-butyl-2-methyl-9H-pyrido[2,3-b]indol-4-ol (2g)



#### CHN Analysis of 9-butyl-2-methyl-9H-pyrido[2,3-b]indol-4-ol (2g)



<sup>1</sup>H NMR of 9-ethyl-2-(pyridin-3-yl)-9*H*-pyrido[2,3-*b*]indol-4-ol (2h)







### LCMS of 9-ethyl-2-(pyridin-3-yl)-9*H*-pyrido[2,3-*b*]indol-4-ol (2h)



# CHN Analysis of 9-ethyl-2-(pyridin-3-yl)-9H-pyrido[2,3-b]indol-4-ol (2h)







<sup>13</sup>C NMR of 9-butyl-2-(thiophen-2-yl)-9*H*-pyrido[2,3-*b*]indol-4-ol (2i)



DEPT of 9-butyl-2-(thiophen-2-yl)-9*H*-pyrido[2,3-*b*]indol-4-ol (2i)



### LCMS of 9-butyl-2-phenyl-9H-pyrido[2,3-b]indol-4-ol (2i)



#### CHN Analysis of 9-butyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2i)



```
<sup>1</sup>H NMR of 9-benzyl-2-phenyl-9H-pyrido[2,3-b]indol-4-ol (2j)
```



<sup>13</sup>C NMR of 9-benzyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2j)



# DEPT of 9-benzyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2j)


#### LCMS of 9-benzyl-2-phenyl-9*H*-pyrido[2,3-*b*]indol-4-ol (2j)



#### CHN Analysis of 9-benzyl-2-phenyl-9H-pyrido[2,3-b]indol-4-ol (2j)







#### <sup>13</sup>C NMR of 4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3a):



#### LCMS of 4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3a):



#### CHN Analysis of 4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3a):











#### LCMS of 9-butyl-2,4-dimethyl-9*H*-pyrimido[4,5-*b*]indole (3b):



#### CHN Analysis of 9-butyl-2,4-dimethyl-9*H*-pyrimido[4,5-*b*]indole (3b):



#### <sup>1</sup>H NMR of 9-butyl-4-methyl-2-phenyl-9*H*-pyrimido[4,5-*b*]indole (3c)







#### LCMS of 9-butyl-4-methyl-2-phenyl-9*H*-pyrimido[4,5-*b*]indole (3c)



#### CHN Analysis of 9-butyl-4-methyl-2-phenyl-9*H*-pyrimido[4,5-*b*]indole (3c)



<sup>1</sup>H NMR of 9-butyl-4-methyl-2-(pyridin-3-yl)-9*H*-pyrimido[4,5-*b*]indole (3d):



<sup>13</sup>C NMR of 9-butyl-4-methyl-2-(pyridin-3-yl)-9*H*-pyrimido[4,5-*b*]indole (3d):



#### LCMS of 9-butyl-4-methyl-2-(pyridin-3-yl)-9*H*-pyrimido[4,5-*b*]indole (3d):



#### CHN Analysis of 9-butyl-4-methyl-2-(pyridin-3-yl)-9H-pyrimido[4,5-b]indole

#### (**3d**):



```
<sup>1</sup>H NMR of 9-butyl-4-methyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-b]indole (3e):
```



### <sup>13</sup>C NMR of 9-butyl-4-methyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-*b*]indole

(**3e**):



#### LCMS of 9-butyl-4-methyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-b]indole (3e):



#### CHN Analysis of 9-butyl-4-methyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-b]indole

(3e):







#### <sup>13</sup>C NMR of 9-hexyl-2,4-dimethyl-9*H*-pyrimido[4,5-*b*]indole (3f)



#### LCMS of 9-hexyl-2,4-dimethyl-9*H*-pyrimido[4,5-*b*]indole (3f)

#### LCMS-2010A DATA REPORT SCHOOL OF CHEMISTRY UNIVERSITY OF HYDERABAD



OPERATOR

#### CHN Analysis of 9-hexyl-2,4-dimethyl-9*H*-pyrimido[4,5-*b*]indole (3f)











#### LCMS of 9-ethyl-4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3g):



#### OPERATOR

#### CHN Analysis of 9-ethyl-4-methyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-b]indole

(**3**g):



## <sup>1</sup>H NMR of 9-benzyl-4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole

(**3h**)



# <sup>13</sup>C NMR of 9-benzyl-4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole(3h)



#### LCMS of 9-benzyl-4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3h)



#### CHN Analysis of 9-benzyl-4-methyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-

#### *b*]indole (3h)



<sup>1</sup>H NMR of 9-hexyl-4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3i)



<sup>13</sup>C NMR of 9-hexyl-4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3i)


#### LCMS of 9-hexyl-4-methyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3i)



### CHN Analysis of 9-hexyl-4-methyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-

### *b*]indole (3i)



S182

## <sup>1</sup>H NMR of 9-butyl-2-(pyridin-3-yl)-9H-pyrimido[4,5-b]indole (3j)



## <sup>13</sup>C NMR of 9-Butyl-2-(pyridin-3-yl)-9H-pyrimido[4,5-*b*]indole (3j)



#### LCMS of 9-Butyl-2-(pyridin-3-yl)-9H-pyrimido[4,5-b]indole (3j)





OPERATOR

### CHN Analysis of 9-Butyl-2-(pyridin-3-yl)-9H-pyrimido[4,5-b]indole (3j)



## <sup>1</sup>H NMR of 9-ethyl-2-phenyl-9*H*-pyrimido[4,5-*b*]indole (3k)



<sup>13</sup>C NMR of 9-ethyl-2-phenyl-9*H*-pyrimido[4,5-*b*]indole (3k)



### LCMS of 9-ethyl-2-phenyl-9*H*-pyrimido[4,5-*b*]indole (3k)



### CHN Analysis of 9-ethyl-2-phenyl-9*H*-pyrimido[4,5-*b*]indole (3k)



## <sup>1</sup>H NMR of 9-ethyl-2-(pyridin-3-yl)-9*H*-pyrimido[4,5-*b*]indole (31)



# <sup>13</sup>C NMR of 9-ethyl-2-(pyridin-3-yl)-9*H*-pyrimido[4,5-*b*]indole (3l)



### LCMS of 9-ethyl-2-(pyridin-3-yl)-9*H*-pyrimido[4,5-*b*]indole (3l)



### CHN Analysis of 9-ethyl-2-(pyridin-3-yl)-9*H*-pyrimido[4,5-*b*]indole (3l)



## <sup>1</sup>H NMR of 9-ethyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3m)





# <sup>13</sup>C NMR of 9-ethyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3m)



### LCMS of 9-ethyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3m)



OPERATOR

### CHN Analysis of 9-ethyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3m)







# <sup>13</sup>C NMR of 9-benzyl-2-(thiophen-2-yl)-9*H*-pyrimido[4,5-*b*]indole (3n)



#### LCMS of 9-benzyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-b]indole (3n)



OPERATOR

### CHN Analysis of 9-benzyl-2-(thiophen-2-yl)-9H-pyrimido[4,5-b]indole (3n)



<sup>1</sup>H NMR of 5-butyl-2-methyl-5*H*-pyrimido[5,4-*b*]indole (30)



<sup>13</sup>C NMR of 5-butyl-2-methyl-5*H*-pyrimido[5,4-*b*]indole (30)



### LCMS of 5-butyl-2-methyl-5*H*-pyrimido[5,4-*b*]indole (30)



S205

### CHN Analysis of 5-butyl-2-methyl-5*H*-pyrimido[5,4-*b*]indole (30)







<sup>13</sup>C NMR of 5-butyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole (3p)



**DEPT of 5-butyl-2-phenyl-5***H***-pyrimido**[**5**,**4***-b*]**indole**(**3p**)



### LCMS of 5-butyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole(3p)



S210

### CHN Analysis of 5-butyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole(3p)



## <sup>1</sup>H NMR of 5-ethyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole (3q)



<sup>13</sup>C NMR of 5-ethyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole (3q)



DEPT of 5-ethyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole (3q)



### LCMS of 5-ethyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole (3q)



### CHN Analysis of 5-ethyl-2-phenyl-5*H*-pyrimido[5,4-*b*]indole (3q)


## <sup>1</sup>H NMR of 5-ethyl-2-(thiophen-2-yl)-5*H*-pyrimido[5,4-*b*]indole (3r)



# <sup>13</sup>C NMR of 5-ethyl-2-(thiophen-2-yl)-5*H*-pyrimido[5,4-*b*]indole (3r)



#### LCMS of 5-ethyl-2-(thiophen-2-yl)-5*H*-pyrimido[5,4-*b*]indole (3r)



#### CHN Analysis of 5-ethyl-2-(thiophen-2-yl)-5*H*-pyrimido[5,4-*b*]indole (3r)



<sup>1</sup>H NMR of 5-butyl-2-(pyridin-3-yl)-5*H*-pyrimido[5,4-*b*]indole (3s)



<sup>13</sup>C NMR of 5-butyl-2-(pyridin-3-yl)-5*H*-pyrimido[5,4-*b*]indole (3s)



#### LCMS of 5-butyl-2-(pyridin-3-yl)-5*H*-pyrimido[5,4-*b*]indole (3s)



#### CHN Analysis of 5-butyl-2-(pyridin-3-yl)-5*H*-pyrimido[5,4-*b*]indole (3s)



## <sup>1</sup>H NMR of 5-butyl-2-(thiophen-2-yl)-5*H*-pyrimido[5,4-*b*]indole (3t)



<sup>13</sup>C NMR of 5-butyl-2-(thiophen-2-yl)-5*H*-pyrimido[5,4-*b*]indole (3t)







#### CHN Analysis of 5-butyl-2-(thiophen-2-yl)-5*H*-pyrimido[5,4-*b*]indole (3t)



## <sup>1</sup>H NMR of (9-ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-b]indol-1-



# <sup>13</sup>C NMR of (9-ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-b]indol-1-



## DEPT of (9-ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-b]indol-1-



#### LCMS of (9-ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-b]indol-1-



OPERATOR

#### CHN Analysis of (9-ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-b]indol-

#### 1-yl)(phenyl)methanone (4a)



S233

## <sup>1</sup>H NMR of (9-ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-*b*]indol-1-



# <sup>13</sup>C NMR of (9-ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-*b*]indol-1-



## DEPT of (9-ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-*b*]indol-1-



#### LCMS of (9-Ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-*b*]indol-1-



#### CHN Analysis of (9-Ethyl-3-nitro-2-phenyl-2,9-dihydro-1*H*-pyrido[2,3-

#### *b*]indol-1-yl)(thiophen-2-yl)methanone (4b)



## **Computational Outputs**

#### For optimized Keto form geometry:

Atomic Number	Co X	o-ordinates Y	s Z
6	1.580309	0.404257	-0.174170
6	1.135106	-0.936472	-0.008198
6	2.082680	-1.965577	0.100368
6	3.439201	-1.640837	0.047311
6	3.860219	-0.307220	-0.111848
6	2.936054	0.735316	-0.223939
6	-0.652397	0.447981	-0.156599
6	-0.307984	-0.895853	0.003261
1	1.757118	-2.993220	0.222828
1	4.183113	-2.428789	0.131349
1	4.922327	-0.079566	-0.146757
1	3.271784	1.761541	-0.340489
7	0.460217	1.241836	-0.274267
6	0.490568	2.697440	-0.416097
1	1.368820	2.945184	-1.019123
1	-0.377932	3.001474	-1.010715
6	0.526828	3.442670	0.922128
1	1.410663	3.160294	1.503391

1	0.565134	4.522708	0.740796
1	-0.362624	3.228156	1.524726
6	-1.334281	-1.903363	0.135153
1	-2.169205	1.858666	-0.303866
6	-2.693258	-1.366545	0.082978
6	-2.977197	-0.038520	-0.074047
7	-1.946120	0.877726	-0.194134
8	-1.099611	-3.128775	0.282599
6	-4.365663	0.533549	-0.130365
1	-4.519625	1.278971	0.660087
1	-4.551827	1.025975	-1.093316
1	-5.107237	-0.257822	-0.002911
1	-3.513412	-2.071253	0.176395

#### For optimized Enol form geometry:

Atomic	<b>Co-ordinates</b>		
Number	X	Y	Z
6	1.551417	0.396505	-0.174771
6	1.091332	-0.943544	-0.010437
6	2.032492	-1.979435	0.093029
6	3.393835	-1.677168	0.035074
6	3.827678	-0.349179	-0.126464
6	2.915270	0.702297	-0.232117

S240

6	-0.698975	0.505649	-0.155629
6	-0.354807	-0.867088	0.001384
1	1.728933	-3.016369	0.217957
1	4.124962	-2.476606	0.116149
1	4.892175	-0.134383	-0.167988
1	3.261685	1.724316	-0.352227
7	0.460426	1.253062	-0.266158
6	0.512487	2.705215	-0.412385
1	1.318083	2.944116	-1.115150
1	-0.429371	3.008886	-0.875161
6	0.715045	3.439981	0.916760
1	1.651714	3.141550	1.400026
1	0.750951	4.521363	0.740312
1	-0.110624	3.231280	1.605376
6	-1.427516	-1.757094	0.119615
1	-0.349563	-3.352709	0.286281
6	-2.728523	-1.241979	0.076779
6	-2.936764	0.135886	-0.083294
7	-1.926300	1.022340	-0.199250
8	-1.286977	-3.103499	0.275083
6	-4.333347	0.703975	-0.134182
1	-4.479040	1.437063	0.668412

1	-4.499983	1.227104	-1.083649
1	-5.091222	-0.078079	-0.031517
1	-3.569510	-1.921483	0.168197

## For optimized Transition state geometry:

Atomic	Co-ordinates		
Number	X	Y	Z
6	1.549569	0.373936	-0.193892
6	1.087344	-0.962198	-0.099379
6	2.002266	-2.017158	-0.059138
6	3.361595	-1.726349	-0.126084
6	3.805737	-0.398800	-0.235272
6	2.911581	0.668655	-0.270372
6	-0.697441	0.507366	-0.112897
6	-0.360555	-0.895431	-0.082859
1	1.655816	-3.040924	0.023648
1	4.087268	-2.531731	-0.093329
1	4.870325	-0.196218	-0.288881
1	3.271633	1.688112	-0.347468
7	0.459102	1.243620	-0.198286
6	0.519677	2.702655	-0.284448
1	1.295591	2.963257	-1.008189
1	-0.433370	3.032881	-0.697066

6	0.781928	3.372001	1.064429
1	1.728691	3.043763	1.499408
1	0.827153	4.456773	0.936948
1	-0.016973	3.146358	1.774299
6	-1.408970	-1.823423	0.396240
1	-1.426126	-1.267975	-1.102371
6	-2.676040	-1.274580	-0.156557
6	-2.911750	0.120602	-0.195056
7	-1.921090	1.021424	-0.120896
8	-1.254335	-2.920414	0.907428
6	-4.309216	0.650635	-0.363101
1	-4.982940	-0.107722	-0.764663
1	-4.708729	0.967924	0.606199
1	-4.316672	1.521678	-1.020516
1	-3.517408	-1.955641	-0.232844